Check for updates

#### **OPEN ACCESS**

EDITED BY Daniela Lucini, University of Milan, Italy

REVIEWED BY Ihori Kobayashi, Walter Reed Army Institute of Research, United States Yoshinari Uehara, Fukuoka University, Japan

\*CORRESPONDENCE Lin Luo 2460022831@gznu.edu.cn

RECEIVED 03 January 2024 ACCEPTED 22 May 2025 PUBLISHED 12 June 2025

#### CITATION

Zhang W, Bi S and Luo L (2025) The impact of long-term exercise intervention on heart rate variability indices: a systematic meta-analysis. Front. Cardiovasc. Med. 12:1364905. doi: 10.3389/fcvm.2025.1364905

#### COPYRIGHT

© 2025 Zhang, Bi and Luo. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# The impact of long-term exercise intervention on heart rate variability indices: a systematic meta-analysis

Wenxin Zhang, Siyuan Bi and Lin Luo\*

School of Physical Education, Guizhou Normal University, Guiyang, China

**Background:** Heart rate variability (HRV) is a critical indicator for assessing autonomic nervous system (ANS) function and is closely associated with both cardiovascular and psychological health. Although previous studies have demonstrated that exercise interventions can improve HRV, their effects vary considerably depending on exercise type, intervention characteristics, and individual differences. This metaanalysis aims to evaluate the impact of long-term exercise interventions on HRV and to explore potential factors that influence these effects.

**Methods:** A systematic search was conducted in PubMed, Cochrane Library, EBSCO, CINAHL, Web of Science, and Embase up to November 20, 2024, to identify randomized controlled trials (RCTs) examining the effects of long-term exercise interventions on HRV. Studies involving short-term interventions, non-original research, or incomplete data were excluded. Two researchers independently performed data extraction and quality assessment. In total, 34 studies involving 1,434 participants were included.

**Results:** Long-term exercise interventions significantly reduced the LF/HF ratio (P < 0.05). Subgroup analyses indicated that the intervention effects were more pronounced in populations with existing health conditions and in interventions lasting  $\geq 8$  weeks. Aerobic training and resistance training demonstrated significant benefits.

**Conclusion:** Long-term exercise interventions significantly reduce the LF/HF ratio and improve ANS balance. These effects, however, are influenced by individual health status, intervention design, and control group conditions. The high heterogeneity among the included studies and limited data on certain intervention characteristics warrant cautious interpretation of the findings. Future research should focus on conducting more high-quality RCTs to validate these results.

**Systematic Review Registration:** https://www.crd.york.ac.uk/PROSPERO/ myprospero, PROSPERO CRD42024541380.

#### KEYWORDS

heart rate variability (HRV), long-term exercise interventions, cardiovascular health, randomized controlled trials, exercise modalities

# 1 Introduction

Heart Rate Variability (HRV) reflects the functional state of the autonomic nervous system (ANS), particularly the dynamic balance between sympathetic and parasympathetic activity (1). It should be emphasized that HRV does not represent the heart's intrinsic ability to regulate its own rate but rather reflects the regulation of cardiac activity by the ANS under various physiological and pathological conditions. Owing to its non-invasive nature, ease of measurement, and the extensive information

it can provide, HRV has been widely applied in fields such as affective science, psychology, and exercise science to evaluate autonomic regulation, cardiovascular health, and the effects of exercise interventions (2, 3).

Studies have demonstrated that reduced HRV is closely associated with an increased risk of various cardiovascular diseases, including hypertension, heart failure, and coronary artery disease (4). Moreover, HRV can be employed to predict risks related to diabetes, autonomic dysfunction, and mental health disorders (5, 6). In the field of exercise science, HRV is regarded as a critical tool for monitoring exercise intensity, evaluating recovery levels, and optimizing training programs (7).

Despite its significant research and application value, existing studies on HRV exhibit notable methodological and outcomerelated inconsistencies. Substantial differences exist in the analytical methods used to evaluate HRV, including time-domain analysis, frequency-domain analysis, and nonlinear analysis, each varying in sensitivity and interpretative capacity (7, 8). For example, time-domain indices, such as the standard deviation of NN intervals (SDNN) and the root mean square of successive differences (RMSSD), primarily reflect overall HRV levels and short-term parasympathetic activity. In contrast, frequencydomain indices, such as the low-frequency to high-frequency (LF/HF) ratio, focus on the relative balance between sympathetic and parasympathetic activity (9). However, the selection and interpretation of these indices often vary across studies, thereby limiting the comparability of results (6).

Additionally, factors such as respiratory rate, depth, and rhythm significantly influence HRV measurements (10). The complex coupling between respiration and heart rate means that changes in respiratory patterns can affect HRV, particularly during social, emotional, and cognitive tasks (11). For instance, studies have shown that social-emotional tasks can reduce respiratory variability, even in situations that elicit positive emotions, which may indirectly affect HRV assessments (12).

The effects of different types of exercise interventions on HRV also vary significantly. Aerobic exercise is generally associated with notable improvements in HRV, reflecting enhanced parasympathetic activity (13). In contrast, the effects of resistance training are more complex and may depend on factors such as training intensity and the individual's baseline health status (14). Other forms of exercise, such as interval training, require further investigation to clarify their impact on HRV. Furthermore, individual differences (e.g., age, gender, health status) play a significant role in modulating the effects of exercise interventions on HRV, with distinct patterns of HRV changes observed between healthy individuals and patients with cardiovascular diseases (15).

Recent studies have explored the cumulative effects of exercise interventions on heart rate variability (HRV) through evidencebased methods. Yang et al. conducted a network meta-analysis (NMA) and found that high-intensity interval training (HIIT) had the most significant improvement on SDNN and RMSSD, while combined training (CBT) and resistance training (RT) showed the best effects on LF and HF power, respectively (16). Amekran et al. further demonstrated through a systematic review and meta-analysis that exercise training significantly improved SDNN, RMSSD, and HF power in healthy adults, confirming the positive regulatory role of exercise on the autonomic nervous system (17). Disessa et al. found that exercise interventions significantly improved HRV indicators, particularly SDNN and RMSSD, in hemodialysis patients (15). However, these studies primarily focused on healthy populations or specific disease groups, lacking systematic analysis of the long-term effects of exercise interventions, especially across different ages, genders, and special populations. Additionally, existing research has been insufficient in comparing mind-body exercises (e.g., yoga) with other forms of exercise.

Building on previous research, this study aims to further elucidate the sustained effects of long-term exercise interventions on HRV through a systematic meta-analysis. The research will focus on the specific impacts of different exercise modalities (e.g., aerobic training, resistance training, high-intensity interval training, and mind-body exercises) on HRV, with a particular emphasis on multiple outcome indicators, including SDNN, RMSSD, LF, HF, and the LF/HF ratio. Additionally, the study will incorporate long-term exercise intervention research targeting both healthy individuals and patients to evaluate the effects of exercise interventions in these populations. Moreover, this study will explore the influence of factors such as age heterogeneity and BMI on the research outcomes, providing a more comprehensive evidence base for exercise-induced improvements in cardiac autonomic function and the reduction of cardiovascular risk in adults.

# 2 Methods

# 2.1 Protocol and registration

This study conducted a computer-assisted systematic literature search (Register number: CRD42024541380) in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines.

# 2.2 Study design

This study adopted a systematic meta-analytic approach to comprehensively evaluate the overall impact of long-term exercise interventions on Heart Rate Variability (HRV) indices. The analysis focused on the effects of various exercise modalities, including high-intensity interval training (HIIT), aerobic training (AT), resistance training (RT), and mind-body training (MBT), on multiple HRV parameters, such as SDNN (Standard Deviation of NN intervals), RMSSD (Root Mean Square of Successive RR Interval Differences), LF (Low-Frequency component), HF (High-Frequency component), and the LF/HF ratio. Table 1 provides a summary of the physiological significance of each HRV index, thereby offering insights into their roles in reflecting autonomic nervous system function. By examining changes in these indices, the study thoroughly

TABLE 1 Intrinsic	physiological	significance	of	heart	rate	variability
(HRV) indices.						

HRV index	Intrinsic physiological significance
SDNN	Reflects the overall level of heart rate variability and represents the overall regulatory capacity of the autonomic nervous system on the heart. Higher SDNN values indicate better overall autonomic nervous function.
RMSSD	Reflects the root mean square of successive differences between adjacent RR intervals, primarily representing parasympathetic nervous activity. Higher RMSSD values suggest stronger parasympathetic nervous activity.
LF	Reflects the low-frequency component of heart rate variability, representing the combined regulatory effects of both sympathetic and parasympathetic nervous systems, but mainly associated with sympathetic nervous activity. Higher LF values indicate stronger sympathetic nervous activity.
HF	Reflects the high-frequency component of heart rate variability, primarily representing parasympathetic nervous activity and closely related to respiratory rate. Higher HF values suggest stronger parasympathetic nervous activity.
LF/HF ratio	Reflects the balance between sympathetic and parasympathetic nervous systems, representing the relative proportion of sympathetic and parasympathetic nervous activities. A higher LF/HF ratio indicates a relative predominance of sympathetic nervous activity, while a lower ratio suggests a relative predominance of parasympathetic nervous activity.

assessed the influence of exercise interventions on autonomic regulation and explored potential variations across different exercise modalities and health populations.

# 2.3 Data sources and search strategy

As of November 20, 2024, a comprehensive and systematic literature search was conducted for this study, utilizing major academic databases including PubMed, The Cochrane Library, EBSCO, CINAHL, Web of Science, and Embase. The objective was to evaluate the impact of various exercise interventions on HRV. The assessment process included a meticulous examination of titles, abstracts, and full texts to ascertain the relevance and eligibility of the identified literature for inclusion in this review. Detailed search methodologies, encompassing specific search terms, Boolean operators, and inclusion/exclusion criteria, are presented in Table 2. This approach facilitates a transparent, systematic, and reproducible literature selection process.

# 2.4 Inclusion and exclusion criteria

#### 2.4.1 Inclusion criteria

#### 2.4.1.1 Population

Studies that evaluated the effects of long-term exercise interventions on HRV in humans, with no restrictions on age, gender, or health status, were included.

#### 2.4.1.2 Interventions

Studies had to evaluate the effects of one of the following training modalities: HIIT, AT, RT, or MBT. The intervention was

TABLE 2 Literature search strategy.

Retrieve content	Search query
HRV	<pre>(((((((ALL = (Heart rate variability)) OR ALL = (heart rate)) OR ALL = (Rate variability)) OR ALL = (heart rate variability)) OR ALL = (heart beat variability)) OR ALL = (heart rate variation)) OR ALL = (heart beat variation)) OR ALL = (autonomic nervous system)) OR ALL = (autonomic nervous system)</pre>
HIIT	((((((((((((((((((((((((((((((((((((
AT	((((ALL = (Aerobic training)) OR ALL = (endurance training)) OR ALL = (Cardiopulmonary training)) OR ALL = (Oxygen training)) OR ALL = (Aerobic endurance training)
RT	(((((Resistance training) OR ALL = (Resistance exercise)) OR ALL = (Resistance)) OR ALL = (Resistance exercise)) OR ALL = (Strength exercise)) OR ALL = (Strength training)
MBT	(((((ALL = (Mind-Body Training)) OR ALL = (Physical and mental exercises)) OR ALL = (tai chi)) OR ALL = (Tai chi chuan)) OR ALL = (a kind of traditional Chinese shadowboxing)) OR ALL = (yoga)

HIIT, high-intensity interval training; AT, aerobic training; RT, resistance training; MBT, mind-body training.

required to involve a frequency of at least once per week and a minimum duration of two weeks to assess its impact on autonomic nervous function.

#### 2.4.1.3 Control group

The control group consisted of participants who either maintained their usual lifestyle or treatment, or took part in other interventions not primarily targeting cardiovascular or autonomic adaptation.

#### 2.4.1.4 Outcomes

Studies needed to report at least one static HRV measurement lasting a minimum of 5 min. They also had to include at least one HRV domain—time-domain indices (e.g., SDNN, RMSSD) or frequency-domain indices (e.g., LF, HF, LF/HF)—to assess changes in autonomic nervous function.

### 2.4.1.5 Study design

Only RCTs were included to ensure the quality and reliability of the results.

#### 2.4.2 Exclusion criteria

#### 2.4.2.1 Population restrictions

Studies involving participants with severe mobility impairments were excluded, as their condition could affect their ability to participate in certain training modalities. Additionally, the raw data of individual participants were not directly examined in this analysis, necessitating this exclusion. Interventions: To more accurately evaluate the effects of single training modalities, studies combining multiple training methods were excluded.

#### 2.4.2.2 Language restrictions

Non-English language articles were excluded to ensure language homogeneity and consistency in research analysis.

#### 2.4.2.3 Study design

Retrospective studies and other non-randomized controlled trial designs were excluded.

#### 2.4.2.4 Acute interventions and data integrity

Studies focusing on acute interventions (i.e., short-term effects of a single training session) were excluded. Additionally, studies with incomplete outcome indicator information or those where the required data could not be obtained through author consultation were excluded.

### 2.5 Data extraction and processing

In accordance with meta-analysis guidelines, this study implemented a double-blind literature screening process, independently conducted by two researchers. Initially, studies were preliminarily screened based on titles and abstracts to identify those meeting the inclusion criteria or with unclear eligibility. Subsequently, full-text reviews were performed, during which each researcher independently assessed the eligibility of articles for inclusion. At the conclusion of each screening phase, discrepancies were resolved through discussion and consensus. Data were independently extracted from each included study using a standardized extraction form specifically designed for this review. Extracted information encompassed study characteristics (e.g., source, first author, publication year), participant details (e.g., age, gender, sample size), intervention specifics (e.g., type, frequency, intensity, duration, and control group conditions), and outcome measurement tools. Key outcomes, including mean values and standard deviations (SD) for time-domain (e.g., SDNN, RMSSD) and frequency-domain metrics (e.g., LF, HF, LF/HF), were also extracted. For studies with partially reported or graphically presented data, authors were contacted via email to obtain complete original datasets.

To ensure data extraction accuracy and consistency, discrepancies were addressed as follows: First, a standardized extraction form was developed, clearly defining variables to be extracted, and data were independently extracted by two researchers. Following extraction, results were compared, discrepancies were identified, and consensus was reached through discussion. In cases of unresolved disagreements, a third researcher arbitrated. For studies with missing or incomplete data, authors were contacted via email to obtain data information. Additionally, researchers underwent pre-extraction training and calibration exercises to ensure a uniform understanding of extraction protocols. Extracted data were subjected to multiple rounds of verification and cross-validation to ensure reliability. All discrepancies and their resolution methods were meticulously documented. To address potential inconsistencies in data formats and units across studies, the following measures were implemented: Variables were converted to standardized units (e.g., SDNN and RMSSD were converted to milliseconds). For studies with inconsistent or missing data formats, authors were contacted to obtain original datasets, followed by cross-validation. All converted data underwent rigorous verification to ensure accuracy and comparability.

### 2.6 Quality assessment

Independent researchers were responsible for data extraction and quality assessment. Included studies had to measure timedomain (SDNN, RMSSD) and frequency-domain (LF, HF, LF/ HF) indices before and after the intervention. These indices served to assess changes in HRV. Efforts were made to contact authors via email to obtain raw data for studies that reported incomplete data or provided data solely in chart form. Studies that failed to provide these measurements were excluded to ensure the interpretability and significance of the meta-analysis. The assessment focused on the completeness and consistency of data, as well as the rigor of study design. The quality assessment results for each study were used in subsequent data analyses to ensure the accuracy and reliability of the findings.I.

### 2.7 Data analysis

All statistical analyses were performed using Review Manager (version 5.4, The Nordic Cochrane Centre) and Stata (version 16, StataCorp LLC). The meta-analysis separately measured common time-domain HRV indices (SDNN, RMSSD) and frequencydomain indices (LFnu, HFnu, LF/HF). The primary outcome measures were the mean (M) and standard deviation (SD) of these indices. For each study's intervention and control groups, post-intervention M ± SD and the number of participants were entered into Review Manager 5.4. These data were used to calculate the standardized mean difference between changes in the intervention and control groups for each study. For studies with inconsistent units, conversions were made to milliseconds (ms) for SDNN and RMSSD, and to natural logarithm (Ln) form for LFnu and HFnu, ensuring consistency in the analysis. A fixed-effect model was adopted when p < 0.1 and  $I^2 < 50\%$ ; a random-effects model was employed when  $p \ge 0.1$  and  $I^2 \ge 50\%$ , accompanied by subgroup analyses to explore sources of heterogeneity. For continuous data, depending on the consistency of measurement tools, either the weighted mean difference (WMD) or standardized mean difference (SMD) was used as the effect size. All effect sizes (ESs) were presented with 95% confidence intervals (95% CI) and interpreted based on the magnitude of the ESs. The level of significance was set at p < 0.05. If more than 10 studies were included, funnel plots were used to assess publication bias, and sensitivity analyses for timedomain and frequency-domain indices were performed using Stata 16 to evaluate the stability of the results.

# **3** Results

### 3.1 Study selection

A comprehensive search of the main electronic databases yielded a total of 46,957 research records. After the removal of 1,363 duplicates, the remaining 45,594 articles underwent an initial screening process. This stage primarily involved filtering based on titles and abstracts, leading to the exclusion of 45,455 articles unrelated to the research theme. Consequently, 139 articles were deemed suitable for full-text evaluation. During the full-text review phase, 105 articles were excluded for failing to meet the predetermined inclusion criteria. These excluded articles consisted of studies with acute intervention data (58 articles), non-RCTs (24 articles), studies with incomplete HRV data (18 articles), and studies with unspecified outcome units (5 articles). Ultimately, 34 studies satisfied the established inclusion criteria and were selected for inclusion in this review. The detailed process of the literature search and screening is illustrated in Figure 1.

### 3.2 Characteristics of included studies

### 3.2.1 Study design

This meta-analysis encompasses 34 studies, of which 25 utilized a randomized controlled trial design (7, 15–44), and 5 were multi-arm randomized parallel group controlled interventions (41–43, 45, 46), and 2 were single-blind randomized controlled trials (44, 47). Detailed study designs and control group conditions are presented in Table 3.

#### 3.2.2 Participants

The included studies comprised a total of 1,434 participants, ranging in age from  $11 \pm 0.6$  to  $67 \pm 7$  years. Of these, 5 studies focused on the elderly population (aged  $\geq 65$  years) (15, 18, 42, 48, 49), 2 targeted children and adolescents (aged 10–17 years) (22, 39), and 19 aimed at adults (aged 18–65 years) (17, 19, 20, 22, 25, 26, 28, 30, 33, 34, 36, 41, 44–47, 50–52). In terms of gender, 9 were female-only (18, 20, 25, 30, 34, 44, 45, 52, 53), and 15 included both males and females (7, 15, 17, 19, 23, 26, 28, 33, 39, 41, 42, 47, 50, 51). 12 studies involved healthy populations (17, 18, 20, 21, 26, 33, 34, 39, 45, 50, 53), while 14 focused on patients with conditions like hypertension diabetes, various forms of heart failure, and chronic obstructive pulmonary disease, which are often associated with autonomic cardiac dysfunction (19, 22, 25, 28, 30, 41, 42, 44, 46–49, 51, 54).

#### 3.2.3 Interventions

The analyzed studies implemented at least one of the training modalities such as HIIT, AT, RT, or MBT. HIIT was the primary intervention in 8 studies (22, 23, 25, 26, 28, 39, 41, 50), encompassing regular circuit training, power cycling, treadmill exercises, etc.; 3 studies used AT (15, 17, 48), primarily in the

form of brisk walking or jogging; 7 studies adopted RT (18–20, 42, 47, 49, 52); and 7 studies incorporated MBT (33, 34, 44–46, 51, 53), such as yoga or Tai Chi. The majority of studies had an intervention frequency of  $\geq$ 3 times per week and a duration of  $\geq$ 8 weeks.

### 3.2.4 Outcome measures

All studies reported at least one objective HRV measurement. 19 studies involved SDNN (7, 15, 17, 18, 20, 21, 23, 24, 26, 28, 29, 33, 35, 39, 40, 47, 48, 50, 53), 21 addressed RMSSD (15, 18, 21-26, 29, 30, 33, 35, 39-41, 44, 46-50), twenty-three focused on LF and HF (15-19, 23, 25, 27, 28, 30-32, 34, 35, 38, 42, 43, 45, 46, 49, 53), and 23 included LF/HF ratio (15, 17-19, 23, 25, 26, 28, 30, 32, 34, 35, 38, 39, 42-44, 46-51, 53). The majority of the studies used Polar Pro straps or other Polar devices for measurement, a few employed Suunto devices, while others utilized computer and commercial systems (Oxford Instruments, Excel ECG Playback System-Rel8.5), portable ECG Holter monitors worn for 24 h (Tracker, Reynolds Medical Ltd., Hertfordshire, UK), ultrasonic monitors (HRV, 8Z11, Wegene Technology, Taiwan), Powerlab data acquisition systems (Data Acquisition Corporation, Colorado Springs, CO, USA), digital ECGs (Micromed, sampling rate: 250 Hz), (UFI, Pneumotrace 2, 1998, California, USA), among other instruments for sampling. One study did not specify the measurement tool used.

### 3.3 Risk of bias

The quality of the included studies was assessed using the Cochrane Collaboration's tool in Review Manager 5.4. This process was independently conducted by two reviewers and covered seven domains (Figure 2): selection bias, performance bias, detection bias, attrition bias, reporting bias, and other potential sources of bias. The risk of bias in each domain was categorized as "low risk," "high risk," or "unclear risk."

The criteria for "low risk" included the following: clear randomization methods and allocation concealment to ensure the grouping process was not compromised; the use of double-blind designs, where both investigators and participants were blinded to group assignments; clear blinding of outcome assessors to prevent subjective judgments from influencing results; complete follow-up data with low attrition rates (typically below 20%) or sensitivity analyses indicating that attrition had no significant impact; pre-registration of study protocols with all pre-specified outcomes reported, avoiding selective reporting; and no other sources of bias that could affect results, such as imbalances in baseline characteristics or undisclosed conflicts of interest. Domains meeting these criteria were rated as "low risk," while those failing to meet the criteria were rated as "high risk" or "unclear risk."

The results of the risk of bias assessment are presented in Figure 3.



# 3.4 Main research findings

### 3.4.1 Time-Domain analysis

In the analysis of changes in SDNN (see Figure 4), a total of 19 studies involving 749 participants were included to compare postintervention SDNN changes between the exercise intervention group and the control group. The meta-analysis indicated that the improvement in SDNN in the intervention group was minimal compared to the control group and did not reach statistical significance (SMD = 0.06, 95% CI: -0.09 to 0.20, P = 0.43). Moreover, the overlapping confidence intervals between groups suggested that the difference may not be significant. Heterogeneity analysis revealed low variability among the included studies ( $I^2 = 0\%$ ).

Regarding changes in RMSSD in HRV (see Figure 5), this meta-analysis included 21 studies involving 829 participants. The results showed that the effect of exercise intervention on RMSSD was small compared to the control group (SMD = 0.09, 95% CI:

#### TABLE 3 Intervention characteristics.

Author (Year)	n (E: exercise group; C: control group	(Female/ Male)	Participant age (Mean <u>+</u> SD)	Research design	Intervention content	Frequency, periodicity	Participants or Subjects	Control Group Intervention Content	Outcome measures
A. Borghi-Silv	E: 10	3/7	67 ± 7	RCT	AT	Three times/week,	Patients with chronic obstructive	No Exercise	Heart rate, oxygen consumption, carbon
et al. (2015)	C: 10	5/5	66 ± 10			12 weeks	pulmonary disease (COPD)	Interventions	dioxide output, SDNN,RMSSD,LF,HF,LF/ HF, etc.
A. M. Gerage	E: 15	15/0	$65.5 \pm 5.0$	RCT	RT	Three times/week,	Healthy elderly women	low-intensity activities	Resting systolic pressure, diastolic
et al. (2012)	C: 14	14/0	66.2 ± 4.1			12 weeks			pressure, mean blood pressure, SDNN, RMSSD,LF,HF,LF/HF, etc.
Alireza	E: 14	0/14	53.90 ± 3.44	RCT	HIIT	Three times/week,	Men aged 50–70 who have	No Exercise	Maximum heart rate, resting heart rate,
Ghardashi-Afousi et al. (2018)	C: 14	0/14	58.80 ± 4.41			6 weeks	undergone coronary artery bypass graft surgery in the past six weeks.	Interventions	resting diastolic pressure, resting systolic pressure, RMSSD,LF/HF, etc.
Anneke van	E: 29	42/67	$11.07\pm0.81$	RCT	HIIT	Three times/week,	Children between the ages of 10	No Exercise	SDNN,RMSSD,LF,HF,LF/HF
Biljon et al. (2018)	C: 24					5 weeks	and 13 with no clinical evidence of known cardiovascular disease or any medical conditions that would limit exercise training.	Interventions	
Bandi Hari	E: 44	12/32	$49.34 \pm 5.70$	RCT	MBT	Three times/week,	Patients with heart failure	No Exercise	Heart rate, blood pressure, cardiac
Krishna et al. (2014)	C: 48	16/32	$50.14 \pm 4.54$	_		12 weeks		Interventions	autonomic function LF,HF,LF/HF, and myocardial oxygen consumption, etc.
Birinder	E: 18	14/4	$37 \pm 12$	RCT	MBT	Three times/week,	Full-time scholars, staff, or	No Exercise	SDNN,RMSSD,LF/HF, musculoskeletal
S. Cheema et al. (2013)	C: 19	16/3	39 ± 13			10 weeks	graduate students	Interventions	health (such as push-ups, side bridge, sit- and-reach tests), and psychological indicators (such as state and trait anxiety, quality of life, and job satisfaction), etc.
Bruna Gallo-Silva	E: 10	Not specified	$66.3\pm6.5$	RCT	AT	Three times/week,	Patients with chronic obstructive	No Exercise	SDNN,RMSSD,LF,HF,LF/HF
et al. (2019)	C: 9		66.5 ± 9.5			8 weeks	pulmonary disease (COPD)	Interventions	
Djordje	E: 9	3/5	49 ± 13	RCT	RT	Three times/week,	Patients with non-alcoholic fatty	No Exercise	LF,HF,LF/HF and autonomic and cardiac
G. Jakovlevic et al. (2013)	C: 8	2/7	62 ± 7			8 weeks	liver disease (NAFLD)	Interventions	hemodynamic measurements at rest and submaximal exercise (50% of peak oxygen consumption), etc.
Gianluca Vernillo	E: 9	9/0	$24.3 \pm 3.7$	RCT	HIIT	Three times/week,	Male adults	No Exercise	SDNN,RMSSD
et al. (2015)	C: 9	9/0				8 weeks		Interventions	
Hélcio Kanegusuku, PhD et al. (2017)	E: 15	2/13	67 ± 8	Randomized parallel controlled trial	RT	Three times/week, 12 weeks	Patients with Parkinson's disease	No Exercise Interventions	Cardiac autonomic regulation (i.e., assessment of sympathetic and parasympathetic nervous system regulation of the LF,HF,LF/HF spectral analysis), etc.
	C: 16	5/11	68 ± 10						
I-Hua Chu et al.	E: 26	26/0	$27.58 \pm 6.12$	RCT	MBT	Two times/week, 8	Healthy women	No Exercise	LF,HF,LF/HF with psychological
(2015)	C: 26	26/0	24.85 ± 5.17			weeks		Interventions	measurement indicators.
I-Hua Chu et al.	E: 13	13/0	33.08 ± 9.11	RCT	MBT	Two times/week,	Women with depression	No Exercise	SDNN,LF,HF,LF/HF depression
(2016)	C: 13	13/0	$32.38 \pm 8.27$			12 weeks		Interventions	symptoms, and perceived stress.

(Continued)

Author (Year)	n (E: exercise group; C: control group	(Female/ Male)	Participant age (Mean <u>+</u> SD)	Research design	Intervention content	Frequency, periodicity	Participants or Subjects	Control Group Intervention Content	Outcome measures
Jesús Alarcón- Gómez et al. (2021)	E: 11 C: 8	6/5 4/4	$38 \pm 5.5$ $35 \pm 8.2$	Randomized parallel controlled trial	нит	Three times/week, 6 weeks	Type 1 diabetes patients	No Exercise Interventions	Maximum oxygen consumption, body composition, RMSSD,LF/HF, fasting blood sugar, etc.
Karavirta et al.	E: 26	26/0	52 ± 7	RCT	RT	Two times/week,	Middle-aged women	No Exercise	SDNN,LF/HF
(2013)	C: 17	17/0	$52 \pm 8$			21 weeks		Interventions	
Kellie Toohey	E: 6	6/0	$60 \pm 8.12$	RCT	HIIT	Three times/week,	Breast cancer survivors	No Exercise	Cardiopulmonary health (VO2 peak),
et al. (2020)	C: 6	6/0	61 ± 7.92			12 weeks		Interventions	resting RMSSD,LF,HF,LF/HF, and salivary biomarkers, etc.
Maharana	E: 45	45/0	$26.23 \pm 2.98$	Randomized two-	MBT	Three times/week,	Healthy pregnant women	low-intensity activities	Perceived stress, cardiac autonomic
Satyapriya et al. (2008)	C: 45	45/0	$25.47 \pm 2.87$	arm experiment		36 weeks			response, LF,HF,LF/HF, etc.
Patricia	E: 8	3/5	$20.85 \pm 1.7$	RCT	HIIT	Three times/week,	Hypertensive patients	No Exercise	Muscle endurance and performance,
Concepción García-Suárez et al. (2022)	C: 6	1/5	23.66 ± 2.6			8 weeks		Interventions	SDNN,RMSSD,LF,HF,LF/HF, etc.
Preeyaphorn	E: 10	2/8	$22.0 \pm 0.8$	RCT	HIIT	Three times/week,	Young individuals with low	No Exercise	HRV (time domain: SDNN and RMSSD,
Songsorn et al. (2021)	C: 11	4/7	21.7 ± 0.8			6 weeks	physical activity	Interventions	frequency domain: LF, HF, and LF/HF ratio), and resting heart rate, etc.
Ran L et al.	E: 13	13/0	$22.6\pm2.5$	RCT	RT	Two times/week, 8	Non-professional, anxiety-prone	No Exercise	BMI (Body Mass Index), self-assessment
(2022)	C: 14	14/0	$22.5\pm2.0$			weeks	female college students	Interventions	anxiety scale, SDNN,RMSSD,LF/HF, etc.
Salene M.W.	E: 100	100/0	$54.4 \pm 3.9$	RCT	MBT	Ninety minutes/	Women with symptoms of	No Exercise	SDNN,RMSSD,LF,HF
Jones et al. (2017)	C: 135	135/0	54.1 ± 3.5			week,12 weeks	vascular constriction	Interventions	
Shirley Telles	E: 22	12/10	$34.6 \pm 6.5$	Randomized two-	MBT	One time/week, 3	Patients with chronic lower back	No Exercise	RMSSD,LF,HF,LF/HF
et al. (2016)	C: 23	10/13	36.6 ± 6.0	arm experiment		months	pain	Interventions	
Shuai Zheng et al.	E: 17	11/6	$35.4 \pm 2.1$	Randomized	MBT	Five hours/	People who are healthy but have	No Exercise	State-Trait Anxiety Inventory, Perceived
(2017)	C: 16	14/2	34.6 ± 2.3	three-arm parallel controlled trial		week,12 weeks	anxiety	Interventions	Stress Scale 14 (PSS14), blood pressure, and LF,HF, etc.
Sophie Cassidy	E: 11	2/9	60 ± 3	RCT	HIIT	Three times/	Type 2 diabetes patients	No Exercise	SDNN,LF,HF,LF/HF blood pressure
et al. (2019)	C: 11	3/8	59 ± 3			week,12 weeks		Interventions	variability, and sensitivity of pressure reflex receptors, etc.
Stefano Benítez-	E: 8	15/15	$25.3 \pm 5.3$	RCT	HIIT	Three times/	Healthy adults	No Exercise	Body composition, aerobic and anaerobic
Flores et al. (2019)	C: 6	_	26.2 ± 3.9			week,2 weeks		Interventions	performance, SDNN,RMSSD, and redox status, etc.
Stella V. Philbois	E: 25	25/0	$29 \pm 4$	RCT	HIIT	Three times/	Patients with polycystic ovary	No Exercise	Cardiopulmonary tests, RMSSD,LF,HF,
et al. (2022)	C: 25	25/0	29 ± 5			week,16 weeks	syndrome (PCOS)	Interventions	LF/HF, blood pressure variability (BPV), and spontaneous baroreflex sensitivity (BRS), etc.
Stephen	E: 16	16/0	$23.0 \pm 4.0$	RCT	HIIT	Three times/	Non-smoking, non-exercising,	No Exercise	Peak oxygen consumption (VO <sub>2</sub> peak),
H. Boutcher et al. (2013)	C: 16	16/0	21.1 ± 2.4			week,12 weeks	overweight young women who are healthy	Interventions	heart rate,LF,HF, etc.

(Continued)

10.3389/fcvm.2025.1364905

TADLE	7	Continued
IADLE	э	Continued

Author (Year)	n (E: exercise group; C: control group	(Female/ Male)	Participant age (Mean <u>+</u> SD)	Research design	Intervention content	Frequency, periodicity	Participants or Subjects	Control Group Intervention Content	Outcome measures	
Steve E. Selig,	E: 19	4/15	65 ± 13	RCT	RT	Three times/	Patients with chronic heart	No Exercise	VO <sub>2</sub> peak, resting SDNN,RMSSD,LF,HF,	
PhD et al. (2003)	C: 20	2/18	64 ± 9			week,12 weeks	failure (CHF)	Interventions	LF/HF, blood pressure variability, etc.	
Tseng-Hau Tseng	E: 20	15/5	$61.1 \pm 6.8$	RCT	AT	Three times/	Adults aged $\geq$ 40 with poor sleep	No Exercise	Subjective (Pittsburgh Sleep Quality	
et al. (2017)	C: 20	18/2	$62.2 \pm 7.4$			week,12 weeks	quality	Interventions	Index, PSQI) and objective (actigraphy recording) sleep quality assessment, SDNN,LF,HF,LF/HF etc.	
Wan-An Lu et al.	E: 25	17/18	$57 \pm 4.25$	RCT	MBT	40 min/week, 3	Patients with chronic heart	No Exercise	Lung function, glucose availability, blood	
(2011)	C: 25	13/12	53 ± 3			months	failure	Interventions	lipid levels, and LF,HF, etc.	
Wei Zhou et al. (2017)	E: 57	19/38	<30 years old ( <i>n</i> = 20);	RCT	MBT	Five times/week, 7 weeks	Patients with nasopharyngeal carcinoma	No Exercise Interventions	Scoring on the Multidimensional Fatigue Symptom Inventory. Heart rate variability	
	C: 57	12/45	30–50 years old ( <i>n</i> = 71)						parameters, including normalized low- frequency (nLF) power, normalized high- frequency (nHF) power, and their correlations with CRF (Cardiorespiratory Fitness), etc.	
Sascha Ketelhut	E: 20	10/10	$11 \pm 0.6$	RCT	HIIT	Two times/	Elementary school students	low-intensity activities	SDNN,RMSSD,LF,HF,LF/HF	
(2024)	C: 20	7/13	$11 \pm 0.7$			week,12 weeks				
Blake E. G. Collins (2023)	E: 15	0/15	51.1 ± 5.7	RCT	AT	Three times/week, 12 weeks	Sedentary men with type 2 diabetes	No Exercise Interventions	Cardiorespiratory fitness, SDNN,RMSSD, flow-mediated dilation	
Ganagarajan	C: 15	0/15	$51.2 \pm 7$	Single-blind	MBT	Five times/week,18	Patients with stage I, II, and III			
Inbaraj (2023)	E: 29	29/0	$45.4 \pm 7.7$	randomized		weeks	breast cancer			
	No Exercise Interventions	RMSSD,LF, HF,LF/HF		controlled trial						
	C: 30	30/0	$46.3 \pm 6.1$							
Pooja Bhati	E: 28	15/13	52.8 ± 6.82	Single-blind	RT	Three times/	Patients with type 2 diabetes	No Exercise	SDNN,RMSSD,LF,HF,LF/HF, heart rate	
(2023)	C: 28	17/11	54.0 ± 8.18	randomized controlled trial		week,12 weeks		Interventions	recovery, spontaneous baroreflex sensitivity, biochemical analysis of biomarkers	

HIIT, high-intensity interval training; AT, aerobic training; RT, resistance training; MBT, mind-body training.





#### FIGURE 3

Illustration of literature quantity assessment. Note: A plus sign (+) indicates high methodological quality (low risk of bias); a minus sign (–) indicates low methodological quality (high risk of bias); a question mark (?) indicates unclear methodological quality (insufficient reporting on what occurred during the study).

	ex	ercise	•	C	ontrol			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
A. borghi-silva (2015)	2.77	1.5	10	2.83	1.43	10	2.7%	-0.04 [-0.92, 0.84]	
A. M. Gerage (2012)	3	2.08	15	3.4	3.8	14	3.9%	-0.13 [-0.86, 0.60]	
Anneke van Biljon (2018)	4.33	0.42	30	3.99	0.55	30	7.7%	0.69 [0.16, 1.21]	
Birinder S Cheema(2013)	4.05	0.65	18	3.87	0.44	19	4.9%	0.32 [-0.33, 0.97]	
Blake E. G. Collins (2023)	1.73	1.38	15	1.66	1.2	15	4.1%	0.05 [-0.66, 0.77]	
Bruna Gallo-Silva (2019)	3.12	2.5	10	2.49	1.79	9	2.5%	0.27 [-0.63, 1.18]	
Gianluca Vernillo (2015)	3.36	0.37	9	3.73	0.22	9	2.0%	-1.16 [-2.18, -0.14]	
-Hua Chu(2016)	3.86	3.1	13	3.86	0.56	13	3.5%	0.00 [-0.77, 0.77]	
Karavirta (2013)	1.27	1.25	26	1.67	1.73	17	5.5%	-0.27 [-0.88, 0.34]	
Patricia Concepción García-Suáre(2022)	4.29	3.76	6	3.99	3.04	6	1.6%	0.08 [-1.05, 1.21]	
Pooja Bhati (2023)	1.48	1.12	28	1.34	0.76	28	7.6%	0.14 [-0.38, 0.67]	
Preeyaphorn Songsorn(2021)	4.29	37	10	3.99	3.25	11	2.8%	0.01 [-0.85, 0.87]	
Ran L(2022)	3.68	2.49	13	3.52	2.38	14	3.7%	0.06 [-0.69, 0.82]	
Salene M.W. Jones(2016)	3.4	0.4	100	3.4	0.4	100	27.1%	0.00 [-0.28, 0.28]	
Sascha Ketelhut (2024)	1.74	1.27	20	1.71	1.24	20	5.4%	0.02 [-0.60, 0.64]	
Sophie Cassidy (2019)	3.97	2.7	11	4.02	2.63	11	3.0%	-0.02 [-0.85, 0.82]	
Stefano Benítez-Flores (2019)	1.78	0.86	8	1.32	0.46	6	1.8%	0.60 [-0.49, 1.69]	
Steve E. Selig, Phd (2003)	3.61	3.33	19	3.57	2.95	20	5.3%	0.01 [-0.62, 0.64]	
Tseng-Hau Tseng (2017)	3.19	2.15	18	3.26	2.72	18	4.9%	-0.03 [-0.68, 0.63]	
Total (95% CI)			379			370	100.0%	0.06 [-0.09, 0.20]	+
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 14.65, d	f=18 (P	= 0.69	); I <sup>z</sup> = 0	%					
Test for overall effect: Z = 0.79 (P = 0.43)									-z -i U i z
									Favours exercise Favours [control]

Forest plot of the meta-analysis on the effects of long-term exercise intervention on SDNN.

	ex	ercise		C	ontrol			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
A. borghi-silva (2015)	3.23	1.7	10	2.97	2.37	10	2.4%	0.12 [-0.76, 1.00]	
A. M. Gerage (2012)	2.84	2	15	2.59	2.01	14	3.5%	0.12 [-0.61, 0.85]	
Alireza Ghardashi-Afousi (2018)	3.86	2.81	14	3.67	2.83	14	3.4%	0.07 [-0.68, 0.81]	
Anneke van Biljon (2018)	4.45	0.45	30	3.99	0.72	30	6.8%	0.76 [0.23, 1.28]	
Birinder S Cheema(2013)	3.66	0.97	18	3.73	0.62	19	4.5%	-0.08 [-0.73, 0.56]	
Blake E. G. Collins (2023)	1.53	1.38	15	1.47	1.11	15	3.7%	0.05 [-0.67, 0.76]	
Bruna Gallo-Silva (2019)	3.45	3.17	10	2.24	1.64	9	2.2%	0.45 [-0.46, 1.37]	
Ganagarajan Inbaraj (2023)	1.47	1.16	29	0.96	0.88	30	7.0%	0.49 [-0.03, 1.01]	+
Gianluca Vernillo (2015)	2.51	0.45	9	2.49	0.52	9	2.2%	0.04 [-0.88, 0.96]	
Jesús Alarcón-Gómez(2021)	3.79	3.32	11	3.67	2.8	8	2.3%	0.04 [-0.87, 0.95]	
Kellie Toohey (2020)	3.35	1.62	6	2.95	0.96	6	1.4%	0.28 [-0.86, 1.42]	
Patricia Concepción García-Suáre(2022)	4.4	3.95	6	3.88	2.96	6	1.5%	0.14 [-1.00, 1.27]	
Pooja Bhati (2023)	1.35	0.91	28	1.24	0.74	28	6.8%	0.13 [-0.39, 0.66]	
Preeyaphorn Songsorn(2021)	4.39	4.09	8	4.08	3.45	10	2.2%	0.08 [-0.85, 1.01]	
Ran L(2022)	3.7	2.77	13	3.4	2.71	14	3.3%	0.11 [-0.65, 0.86]	
Salene M.W. Jones(2016)	3.1	0.4	100	3.2	0.4	100	24.3%	-0.25 [-0.53, 0.03]	
Sascha Ketelhut (2024)	1.73	1.38	20	1.68	1.2	20	4.9%	0.04 [-0.58, 0.66]	
Shirley Telles (2016)	4.37	3.93	21	3.47	3	21	5.1%	0.25 [-0.35, 0.86]	
Stefano Benítez-Flores (2019)	1.39	0.88	8	0.92	0.28	6	1.6%	0.63 [-0.46, 1.73]	
Stella V. Philbois (2022)	3.98	3.29	25	3.95	3.49	25	6.1%	0.01 [-0.55, 0.56]	
Steve E. Selig, Phd (2003)	3.16	2.86	19	3.12	2.8	20	4.8%	0.01 [-0.61, 0.64]	
Total (95% CI)			415			414	100.0%	0.09 [-0.05, 0.23]	◆
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 16.63, dt	f= 20 (P	= 0.68	); $ ^2 = 0$	%					
Test for overall effect: Z = 1.29 (P = 0.20)									Eavours [experimental] Eavours [control]
									· steare [experimental] · areare [centrol]
UKE 5									

-0.05 to 0.23), and it did not reach statistical significance (*P* = 0.20). Heterogeneity analysis indicated low variability among the included studies ( $I^2 = 0\%$ ).

intervention types, sample characteristics, or study designs on the results.

#### 3.4.2 Frequency-domain analysis

In the analysis of post-intervention LF changes (see Figure 6), a total of 26 studies involving 1,254 participants were included. The meta-analysis indicated a very small SMD between the intervention and control groups (SMD = -0.03, 95% CI: -0.16 to 0.09), which did not reach statistical significance (P = 0.60). Heterogeneity analysis revealed low variability among the included studies ( $I^2 = 12\%$ ).

In the analysis of post-intervention HF changes (see Figure 7), a total of 26 studies involving 1,254 participants were included. The results showed an SMD of 0.03 (95% CI: -0.12 to 0.18) between the intervention and control groups, which did not reach statistical significance (P = 0.72). The heterogeneity among studies was 39%, indicating a moderate level of variability.

In the analysis of post-intervention LF/HF changes, a total of 26 studies involving 967 participants were included (see Figure 8). The meta-analysis showed that LF/HF in the intervention group was significantly lower than in the control group (SMD = -0.54, 95% CI: -0.83 to -0.25, P = 0.0002). A reduction in LF/HF indicates decreased sympathetic nervous system activity relative to parasympathetic nervous system activity, suggesting that exercise interventions may improve the balance of the autonomic nervous system. However, despite the significant mean difference observed in the intervention group, heterogeneity among studies was high ( $I^2 = 77\%$ ). Therefore, further subgroup or sensitivity analyses are planned to identify sources of heterogeneity and to explore the effects of different

# 3.5 Subgroup analysis of LF/HF ratio

#### 3.5.1 Individual factors

Table 4 presents the effects of different subgroups on LF/HF and their heterogeneity.

A total of 24 studies were included in the subgroup analysis of age effects on LF/HF. In the 18–65 age group, SMD = -0.57 (95% CI: -0.94 to -0.20, P = 0.003,  $I^2 = 82\%$ ). In the 65+ age group, SMD = -0.60 (95% CI: -1.11 to -0.08, P = 0.02,  $I^2 = 53\%$ ). Although the exercise intervention showed a significant effect on the LF/HF ratio in the 18–65 age group and the group over 65 years, the between-group comparison with a *p*-value of 0.94 indicates that the impact of the exercise intervention on the two age groups is not significantly different.

A total of 26 studies were included in the subgroup analysis of health status effects on LF/HF. In healthy individuals, SMD = -0.14 (95% CI: -0.38 to 0.11, P = 0.27,  $I^2 = 39\%$ ). In individuals with illnesses, SMD = -0.87 (95% CI: -1.31 to -0.43, P < 0.001,  $I^2 = 80\%$ ). The study results indicate that the exercise intervention effect in the healthy group is not significant compared to the control group, whereas the effect in the disease group is significant. The between-group comparison yielded a p-value of 0.004, and the confidence intervals for the two groups do not overlap, indicating a significant difference in the intervention outcomes between the healthy and disease groups.

A total of 24 studies were included in the subgroup analysis of gender effects on LF/HF. In the female group, SMD = -0.56 (95% CI: -1.19 to 0.08, P = 0.09,  $I^2 = 88\%$ ). In the mixed-gender group, SMD = -0.60 (95% CI: -1.11 to -0.08, P = 0.002,  $I^2 = 67\%$ ). The

Study of Subgroup         Mean         SD         Total         Weight         IV, Random, 55% CI           A. borghi-silva (2015)         0.49         0.24         10         0.41         0.23         10         1.8%         0.33 [-0.56, 1.21]           A. M. Gerage (2012)         4.15         2.91         15         4.21         2.74         14         2.6%         -0.02 [-0.75, 0.71]           Anneke van Biljon (2018)         3.49         0.48         30         3.47         0.73         30         5.0%         0.03 [-0.47, 0.54]           Bandi Hari Krishna (2014)         3.41         2.13         44         3.93         2.24         48         7.1%         -0.24 [-0.65, 0.17]           Bruna Gallo-Silva (2019)         4.01         2.39         10         4.24         2.48         8         1.6%         -0.01 [-1.06, 0.85]           Ganagarajan Inbaraj (2023)         6.17         3.69         29         8.66         3.13         30         4.7%         -0.72 [-1.25, -0.19]           Hélcio Kanegusuku, PhD (2017)         3.85         1.69         3.93         1.08         6         1.1%         0.02 [-0.52, 0.57]           Hua Chu(2016)         3.5         2.69         13         3.94         3	Int     IV, Random, 95% CI       3%     0.33 [-0.56, 1.21]       3%     0.03 [-0.47, 0.54]       1%     -0.02 [-0.75, 0.71]       3%     -0.03 [-0.47, 0.54]       1%     -0.09 [-0.99, 0.81]       3%     -0.09 [-0.99, 0.81]       3%     -0.11 [-1.06, 0.85]       7%     -0.72 [-1.25, -0.19]       7%     -0.15 [-0.92, 0.62]       1%     0.02 [-0.52, 0.57]       1%     0.054 [-0.62, 1.70]       1%     0.05 [-1.18, 1.08]       7%     -0.17 [-0.70, 0.35]       3%     0.04 [-0.82, 0.90]       1%     0.02 [-0.25, 0.30]       1%     0.02 [-0.64, 0.60]       7%     -0.06 [-0.66, 0.55]       2%     1.71 [0.91, 2.51]       3%     -0.04 [-0.87, 0.80]       3%     -0.04 [-0.67, 0.53]       1%     -0.06 [-0.76, 0.63]       1%     -0.02 [-0.58, 0.53]       3%     -0.04 [-0.67, 0.59]       3%     -0.04 [-0.67, 0.53]       3%     -0.04 [-0.67, 0.63]
A. B. Oragin-Sinka (2015)       0.49       0.24       10       0.41       0.23       10       1.83       0.03       [0.05, 0.71]         A. M. Gerage (2012)       4.15       2.91       15       4.21       2.74       14       2.6%       -0.02       [0.75, 0.71]         Anneke van Biljon (2018)       3.49       0.48       30       3.47       0.73       30       5.0%       0.03       [0.47, 0.54]         Bandi Hari Krishna (2014)       3.41       2.13       44       3.93       2.24       48       8       1.6%       -0.01       [0.08]       0.09       [0.99, 0.81]       Djordje G. Jakovlevic (2013)       3.93       2.64       9       4.22       2.88       8       1.6%       -0.11       [1.06, 0.65]       Ganagarajan Inbaraj (2023)       6.17       3.69       29       8.66       3.13       30       4.7%       -0.72 [-1.25, -0.19]         Hélici Kanegusuku, PhD (2017)       3.85       1.79       15       4.14       1.09       15       2.7%       -0.19 [-0.91, 0.53]       I-Hua Chu(2016)       3.52       2.69       13       3.44       3       13       2.4%       -0.17 [-0.70, 0.56]       I-Hua Chu(2016)       3.52       2.69       1.0%       1.14%       0.54 [-0.62, 1.7	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$
A. M. Oetrage (2012)4.152.91154.212.74142.05%-0.02 [-0.75, 0.71]Anneke van Biljon (2018)3.490.48303.470.73305.0%0.03 [-0.47, 0.54]Bandi Hari Krishna (2014)3.412.13443.932.24487.1%-0.24 [-0.55, 0.17]Bruna Gallo-Silva (2019)4.012.39104.242.6191.8%-0.09 [-0.99, 0.81]Djordje G. Jakovlevic (2013)3.932.6494.222.4881.6%-0.11 [-1.06, 0.85]Ganagarajan Inbaraj (2023)6.173.69298.663.13304.7%-0.72 [-1.25, -0.19]Hélcio Kanegusuku, PhD (2017)3.851.79154.141.09152.7%-0.19 [-0.91, 0.53]I-Hua Chu(2016)3.52.69133.943132.4%-0.01 [-0.40, 0.42]Maharana Satyapriya(2008)4.281.79454.262457.0%0.01 [-0.40, 0.42]Patricia Concepción García-Suáre(2022)3.942.5564.093.0261.1%-0.05 [-1.18, 1.08]Pooja Bhati (2023)7.133.13206.91.283203.5%-0.02 [-0.25, 0.30]Salene M.W. Jones(2016)4.132.881004.062.9710012.4%0.02 [-0.25, 0.30]Salene M.W. Jones(2016)4.132.88104.062.9710012.4%0.02 [-0.25, 0.30] <td>3%     -0.02 [-0.7, 0.5, 0.7]       9%     -0.3 [-0.47, 0.54]       1%     -0.24 [-0.65, 0.7]       3%     -0.11 [-1.06, 0.85]       3%     -0.11 [-1.06, 0.85]       7%     -0.72 [-1.25, -0.19]       7%     -0.72 [-0.52, 0.57]       1%     0.02 [-0.52, 0.57]       1%     0.01 [-0.40, 0.42]       1%     0.01 [-0.40, 0.42]       1%     -0.05 [-1.18, 1.08]       7%     -0.17 [-0.70, 0.35]       3%     0.01 [-0.40, 0.42]       1%     0.02 [-0.25, 0.30]       1%     0.02 [-0.26, 0.30]       1%     0.02 [-0.26, 0.30]       1%     0.02 [-0.26, 0.30]       1%     0.02 [-0.58, 0.53]       1%     -0.04 [-0.87, 0.63]       1%     -0.04 [-0.67, 0.59]       1%     -0.02 [-0.36, 0.63]       1%     -0.02 [-0.36, 0.63]       1%     -0.02 [-0.36, 0.31]</td>	3%     -0.02 [-0.7, 0.5, 0.7]       9%     -0.3 [-0.47, 0.54]       1%     -0.24 [-0.65, 0.7]       3%     -0.11 [-1.06, 0.85]       3%     -0.11 [-1.06, 0.85]       7%     -0.72 [-1.25, -0.19]       7%     -0.72 [-0.52, 0.57]       1%     0.02 [-0.52, 0.57]       1%     0.01 [-0.40, 0.42]       1%     0.01 [-0.40, 0.42]       1%     -0.05 [-1.18, 1.08]       7%     -0.17 [-0.70, 0.35]       3%     0.01 [-0.40, 0.42]       1%     0.02 [-0.25, 0.30]       1%     0.02 [-0.26, 0.30]       1%     0.02 [-0.26, 0.30]       1%     0.02 [-0.26, 0.30]       1%     0.02 [-0.58, 0.53]       1%     -0.04 [-0.87, 0.63]       1%     -0.04 [-0.67, 0.59]       1%     -0.02 [-0.36, 0.63]       1%     -0.02 [-0.36, 0.63]       1%     -0.02 [-0.36, 0.31]
Annek van Biljon (2018)       3.49       0.48       30       3.47       0.73       30       5.0%       0.03 [0.47, 0.54]         Bandi Hari Krishna (2014)       3.41       2.13       44       393       2.24       48       7.1%       -0.24 [-0.65, 0.17]         Bruna Gallo-Silva (2019)       4.01       2.39       10       4.24       2.61       9       1.8%       -0.01 [-0.09, 0.81]         Djordje G. Jakovlevic (2013)       3.93       2.64       9       4.22       2.48       8       1.6%       -0.11 [-1.06, 0.85]         Ganagarajan Inbaraj (2023)       6.17       3.69       29       8.66       3.13       30       -0.72 [-1.25, -0.19]         Héicio Kanegusuku, PhD (2017)       3.85       1.79       15       4.14       1.09       15       2.7%       -0.19 [-0.91, 0.63]         Hua Chu(2015)       3.77       2.74       26       3.71       2.69       26       4.4%       0.02 [-0.52, 0.57]         Hua Chu(2015)       3.57       2.74       26       3.93       1.08       6       1.1%       0.04 [-0.40, 0.42]         Maharana Satyapriya(2008)       4.28       1.79       45       4.26       2       45       7.0%       0.01 [-0.40, 0.42] <t< td=""><td><math display="block">\begin{array}{c ccccccccccccccccccccccccccccccccccc</math></td></t<>	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$
Bandi Hari Krishna (2014)       3.41       2.13       44       3.93       2.24       48       7.1%       -0.24 [-0.55, 0.17]         Bruna Gallo-Silva (2019)       4.01       2.39       10       4.24       2.61       9       1.8%       -0.09 [-0.90, 0.81]         Djordje G. Jakovlevic (2013)       3.93       2.64       9       4.22       2.48       8       1.6%       -0.01 [-1.06, 0.85]         Ganagarajan Inbaraj (2023)       6.17       3.69       29       8.66       3.13       30       4.7%       -0.72 [-1.25, -0.19]         Hélcio Kanegusuku, PhD (2017)       3.85       1.79       15       4.14       1.09       15       2.7%       -0.15 [-0.92, 0.62]         I-Hua Chu(2016)       3.5       2.69       13       3.94       3       13       2.4%       -0.15 [-0.92, 0.62]         Kellie Toohey (2020)       5.19       2.85       6       3.93       1.08       6       1.1%       0.05 [-1.18, 1.08]         Pooja Bhati (2020)       7.13       3.13       28       7.69       3.55       28       4.7%       -0.17 [-0.70, 0.35]         Prevaphorn Songsorn(2021)       3.49       3.19       10       3.36       2.98       11       1.9%       0.04 [-0.82, 0	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$
Bruna Gallo-Silva (2019)4.012.39104.242.6191.8%-0.09 [0.99 [0.91]Djordje G. Jakovlevic (2013)3.932.6494.222.4881.6%-0.11 [+1.06, 0.85]Ganagarajan Inbaraj (2023)6.173.69298.663.13304.7%-0.72 [+1.25, -0.19]Hélcio Kanegusuku, PhD (2017)3.851.79154.141.09152.7%-0.19 [-0.91, 0.53]Hua Chu(2016)3.52.69133.943132.4%-0.015 [-0.92, 0.62]Kellie Toohey (2020)5.192.8563.931.0861.1%0.54 [-0.62, 1.70]Maharana Satyapriya(2008)4.281.79454.262457.0%0.01 [-0.40, 0.42]Patricia Concepción García-Suáre(2022)3.942.5564.093.0261.1%-0.05 [-1.18, 1.08]Pooja Bhati (2023)7.133.132.877.693.352.884.7%-0.17 [-0.70, 0.35]Preeyaphorn Songsom(2021)3.493.19103.362.98111.9%0.04 [-0.82, 0.90]Salene M.W. Jones(2016)4.132.881004.062.9710012.4%0.02 [-0.25, 0.30]Sascha Ketelhut (2024)6.743.13206.912.83203.5%-0.02 [-0.64, 0.60]Shirley Telles (2016)3.922.4824.072.281.71 [0.91, 2.51]Sophie Cassidy (2017) <td><math display="block">\begin{array}{c ccccccccccccccccccccccccccccccccccc</math></td>	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$
Djordje G. Jakovlevic (2013)       3.93       2.64       9       4.22       2.48       8       1.6%       -0.11 [-1.06, 0.85]         Ganagarajan Inbaraj (2023)       6.17       3.69       29       8.66       3.13       30       4.7%       -0.72 [-1.25, -0.19]         Helcio Kanegusuku, PhD (2017)       3.85       1.79       15       4.14       1.09       15       2.7%       -0.19 [-0.31, 0.53]         Hua Chu(2015)       3.77       2.74       26       3.71       2.69       26       4.4%       0.02 [-0.52, 0.57]         Hua Chu(2016)       3.5       2.69       13       3.94       3       13       2.4%       -0.015 [-0.32, 0.62]         Kellie Toohey (2020)       5.19       2.85       6       3.93       1.08       6       1.1%       0.05 [-1.18, 1.08]         Pooja Bhati (2023)       7.13       3.13       28       7.69       3.52       28       4.7%       -0.01 [-0.40, 0.42]         Patricia Concepción García-Suáre(2022)       3.94       2.55       6       4.09       3.02       6       1.1%       -0.05 [-1.18, 1.08]       Pooja Bhati (2023)       7.13       3.13       20       5.8       4.7%       -0.01 [-0.40, 0.42]       Salene M.V. Jones(2016)       4.13 </td <td>9%     -0.11 [-1.06, 0.85]       7%     -0.72 [-1.25, -0.19]       9%     -0.19 [-0.91, 0.63]       4%     0.02 [-0.52, 0.57]       1%     -0.15 [-0.92, 0.62]       1%     0.54 [-0.62, 1.70]       9%     -0.17 [-0.70, 0.42]       1%     -0.05 [-1.18, 1.08]       7%     -0.17 [-0.70, 0.35]       1%     0.02 [-0.52, 0.30]       3%     0.04 [-0.82, 0.90]       1%     0.02 [-0.54, 0.60]       7%     -0.06 [-0.66, 0.55]       3%     -0.02 [-0.58, 0.63]       3%     -0.02 [-0.58, 0.63]       3%     -0.04 [-0.87, 0.69]       3%     -0.04 [-0.67, 0.59]       1%     -0.02 [-0.78, 0.63]       3%     -0.04 [-0.76, 0.63]       1%     -0.02 [-0.39, 0.34]</td>	9%     -0.11 [-1.06, 0.85]       7%     -0.72 [-1.25, -0.19]       9%     -0.19 [-0.91, 0.63]       4%     0.02 [-0.52, 0.57]       1%     -0.15 [-0.92, 0.62]       1%     0.54 [-0.62, 1.70]       9%     -0.17 [-0.70, 0.42]       1%     -0.05 [-1.18, 1.08]       7%     -0.17 [-0.70, 0.35]       1%     0.02 [-0.52, 0.30]       3%     0.04 [-0.82, 0.90]       1%     0.02 [-0.54, 0.60]       7%     -0.06 [-0.66, 0.55]       3%     -0.02 [-0.58, 0.63]       3%     -0.02 [-0.58, 0.63]       3%     -0.04 [-0.87, 0.69]       3%     -0.04 [-0.67, 0.59]       1%     -0.02 [-0.78, 0.63]       3%     -0.04 [-0.76, 0.63]       1%     -0.02 [-0.39, 0.34]
Ganagarajan Inbaraj (2023)       6.17       3.69       29       8.66       3.13       30       4.7%       -0.72 [-1.25, -0.19]         Hélcio Kanegusuku, PhD (2017)       3.85       1.79       15       4.14       1.09       15       2.7%       -0.19 [-0.51, 0.53]         I-Hua Chu(2016)       3.7       2.74       26       3.71       2.69       26       4.4%       0.02 [-0.52, 0.57]         I-Hua Chu(2016)       3.5       2.69       13       3.94       3       13       2.4%       -0.15 [-0.92, 0.62]         Kellie Toohey (2020)       5.19       2.85       6       3.93       1.08       6       1.1%       0.05 [-1.18, 1.08]         Patricia Concepción García-Suáre(2022)       3.94       2.55       6       4.09       3.02       6       1.1%       -0.05 [-1.18, 1.08]         Pooja Bhati (2023)       7.13       3.13       28       7.69       3.35       28       4.7%       -0.17 [-0.70, 0.35]         Preveyahorn Songsom(2021)       3.49       3.19       10       3.36       2.98       11       1.9%       0.04 [-0.82, 0.90]       Sascha Ketelhut (2024)       6.74       3.13       20       6.9       12.83       20       3.5%       -0.02 [-0.64, 0.60]       Sh	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$
Hélcio Kanegusuku, PhD (2017)3.851.79154.141.09152.7%-0.19 [-0.91, 0.53]I-Hua Chu(2015)3.772.74263.712.69264.4%0.02 [-0.52, 0.57]I-Hua Chu(2016)3.52.69133.943132.4%-0.15 [-0.92, 0.62]Kellie Toohey (2020)5.192.8563.931.0861.1%0.54 [-0.62, 1.70]Maharana Satyapriya(2008)4.281.79454.262457.0%0.01 [-0.40, 0.42]Patricia Concepción García-Suáre(2022)3.942.5564.093.0261.1%-0.05 [-1.18, 1.08]Pooja Bhati (2023)7.133.132.87.693.352.84.7%-0.17 [-0.70, 0.35]Preeyaphorn Songsom(2021)3.493.19103.362.98111.9%0.04 [-0.82, 0.90]Salene M.W. Jones(2016)4.132.881004.062.9710012.4%0.02 [-0.54, 0.60]Shirley Telles (2016)3.922.48214.072.82213.7%-0.06 [-0.66, 0.55]Shuai Zheng (2017)0.640.40170.570.04172.2%1.71 [0.91, 2.51]Sophie Cassidy (2019)3.871.6113.931.6112.0%-0.04 [-0.87, 0.60]Stelpen H. Boutcher (2013)3.522.74163.72.91162.9%-0.06 [-0.76, 0.63]Steve E. Selig, Phd (2	7%     -0.19 [-0.31, 0.53]       4%     0.02 [-0.52, 0.57]       4%     0.05 [-0.32, 0.62]       1%     0.05 [-0.32, 0.62]       1%     0.01 [-0.40, 0.42]       1%     -0.05 [-1.18, 1.08]       7%     -0.17 [-0.70, 0.35]       3%     0.04 [-0.82, 0.90]       1%     -0.05 [-0.64, 0.60]       7%     -0.07 [-0.76, 0.63]       3%     -0.02 [-0.56, 0.53]       3%     -0.02 [-0.58, 0.53]       3%     -0.02 [-0.78, 0.53]       3%     -0.04 [-0.87, 0.80]       3%     -0.02 [-0.78, 0.53]       3%     -0.02 [-0.78, 0.53]       3%     -0.02 [-0.63, 0.34]
Hua Chu(2015)3.772.74263.712.69264.4%0.02 [-0.52, 0.67]Hua Chu(2016)3.52.69133.943132.4%-0.15 [-0.92, 0.62]Kellie Toohey (2020)5.192.8563.931.0861.1%0.54 [-0.62, 1.70]Maharana Satyapriya(2008)4.281.79454.262457.0%0.01 [-0.40, 0.42]Patricia Concepción García-Suáre(2022)3.942.5564.093.0261.1%-0.05 [-1.18, 1.08]Pooja Bhati (2023)7.133.132.87.693.522.847.1-0.05 [-1.18, 1.08]Prevaphorn Songsom(2021)3.493.19103.562.98111.9%0.04 [-0.82, 0.90]Salene M.W. Jones(2016)4.132.881004.062.9710012.4%0.02 [-0.25, 0.30]Sascha Ketelhut (2024)6.743.13206.912.83203.5%-0.02 [-0.64, 0.60]Shirley Telles (2016)3.922.48214.072.82213.7%-0.06 [-0.66, 0.55]Shuai Zheng (2017)0.640.04170.570.04172.2%1.71 [0.91, 2.51]Sophie Cassidy (2019)3.871.6113.931.6112.0%-0.04 [-0.87, 0.80]Stela V. Philbois (2022)3.762.63253.822.89254.3%-0.02 [-0.58, 0.53]Stephen H. Boutcher (2013)	4%       0.02 [-0.52, 0.57]         4%       -0.15 [-0.92, 0.62]         1%       0.54 [-0.62, 1.70]         9%       0.05 [-1.18, 1.08]         1%       -0.05 [-1.18, 1.08]         9%       -0.07 [-0.70, 0.35]         9%       0.04 [-0.82, 0.90]         9%       -0.07 [-0.70, 0.35]         9%       -0.04 [-0.82, 0.90]         9%       -0.02 [-0.64, 0.60]         9%       -0.06 [-0.66, 0.55]         2%       1.71 [0.91, 2.51]         9%       -0.04 [-0.87, 0.60]         9%       -0.04 [-0.87, 0.63]         9%       -0.04 [-0.87, 0.53]         9%       -0.13 [-0.78, 0.53]         9%       -0.13 [-0.78, 0.53]         9%       -0.13 [-0.78, 0.53]         9%       -0.04 [-0.87, 0.44]         9%       -0.02 [-0.39, 0.34]
Hua Chu(2016)3.52.69133.943132.4%-0.16 [-0.92, 0.62]Kellie Toohey (2020)5.192.8563.931.0861.1%0.54 [-0.62, 1.70]Maharana Satyapriya(2008)4.281.79454.262457.0%0.01 [-0.40, 0.42]Patricia Concepción García-Suáre(2022)3.942.5564.093.0261.1%-0.05 [-1.18, 1.08]Pooja Bhati (2023)7.133.13287.693.35284.7%-0.17 [-0.70, 0.35]Preeyaphorn Songsorn(2021)3.493.19103.362.98111.9%0.04 [-0.82, 0.90]Salene MW, Jones(2016)4.132.881004.062.9710012.4%0.02 [-0.25, 0.30]Sascha Ketelhut (2024)6.743.13206.912.83203.5%-0.02 [-0.64, 0.60]Shirley Telles (2016)3.922.48214.072.82213.7%-0.06 [-0.66, 0.55]Shuai Zheng (2017)0.640.04170.570.04172.2%1.71 [0.91, 2.51]Sophic Cassidy (2019)3.871.6113.931.6112.0%-0.02 [-0.58, 0.53]Stephen H. Boutcher (2013)3.522.74163.72.91162.9%-0.04 [-0.87, 0.63]Steve E. Selig, Phd (2003)3.972.68184.12.47183.2%-0.13 [-0.78, 0.63]Wan-An Lu (2011)<	4%       -0.15 [-0.92, 0.62]         1%       0.54 [-0.62, 1.70]         3%       -0.01 [-0.40, 0.42]         1%       -0.05 [-1.18, 1.08]         7%       -0.17 [-0.70, 0.35]         3%       0.04 [-0.82, 0.90]         1%       0.02 [-0.56, 0.60]         7%       -0.06 [-0.66, 0.55]         3%       0.02 [-0.87, 0.60]         7%       -0.04 [-0.87, 0.60]         3%       -0.02 [-0.58, 0.63]         3%       -0.04 [-0.87, 0.60]         3%       -0.02 [-0.58, 0.63]         3%       -0.04 [-0.87, 0.60]         3%       -0.02 [-0.58, 0.63]         1%       -0.04 [-0.87, 0.60]         3%       -0.02 [-0.78, 0.63]         1%       -0.04 [-0.87, 0.60]         3%       -0.04 [-0.76, 0.63]         1%       -0.04 [-0.7, 0.44]         1%       -0.02 [-0.39, 0.34]
Kellie Toohey (2020)5.192.8563.931.0861.1%0.54 [-0.62, 1.70]Maharana Satyapriya(2008)4.281.79454.262457.0%0.01 [-0.40, 0.42]Patricia Concepción García-Suáre(2022)3.942.5564.093.0261.1%-0.05 [-1.18, 1.08]Pooja Bhati (2023)7.133.13287.693.35284.7%-0.17 [-0.70, 0.35]Preeyaphorn Songsom(2021)3.493.19103.362.98111.9%0.04 [-0.82, 0.90]Salene M.W. Jones(2016)4.132.881004.062.9710012.4%0.02 [-0.26, 0.30]Sascha Ketelhut (2024)6.743.13206.912.82213.7%-0.02 [-0.64, 0.60]Shirley Telles (2016)3.922.48214.072.82213.7%-0.02 [-0.64, 0.60]Shirley Telles (2016)3.922.48214.072.82213.7%-0.02 [-0.68, 0.55]Shuai Zheng (2017)0.640.04170.570.04172.2%1.71 [0.91, 2.51]Sophie Cassidy (2019)3.871.6113.931.6112.0%-0.02 [-0.58, 0.53]Stephen H. Boutcher (2013)3.522.74163.72.91162.9%-0.06 [-0.76, 0.63]Steve E. Selig, Phd (2003)3.972.68184.12.47183.2%-0.13 [-0.76, 0.63]Wan-An Lu	1%       0.54 [-0.62, 1.70]         0%       0.01 [-0.40, 0.42]         1%       0.05 [-1.18, 1.08]         7%       -0.17 [-0.70, 0.35]         3%       0.04 [-0.82, 0.90]         1%       0.02 [-0.25, 0.30]         1%       0.02 [-0.25, 0.30]         1%       0.02 [-0.25, 0.30]         1%       0.02 [-0.25, 0.30]         1%       0.02 [-0.25, 0.30]         1%       0.02 [-0.25, 0.30]         1%       0.02 [-0.25, 0.30]         1%       0.02 [-0.25, 0.30]         1%       0.02 [-0.25, 0.50]         1%       -0.02 [-0.68, 0.55]         1%       -0.02 [-0.58, 0.53]         1%       -0.02 [-0.76, 0.63]         1%       -0.02 [-0.78, 0.53]         1%       -0.02 [-0.34]
Maharana Satyapriya(2008)4.281.79454.262457.0%0.01 [-0.40, 0.42]Patricia Concepción García-Suáre(2022)3.942.5564.093.0261.1%-0.05 [-1.18, 1.08]Pooja Bhati (2023)7.133.13287.693.35284.7%-0.17 [-0.70, 0.35]Preeyaphorn Songsom(2021)3.493.19103.362.98111.9%0.04 [-0.82, 0.90]Salene M.W. Jones(2016)4.132.881004.062.9710012.4%0.02 [-0.25, 0.30]Sascha Ketelhut (2024)6.743.13206.912.83203.5%-0.02 [-0.64, 0.60]Shirley Telles (2016)3.922.48214.072.82213.7%-0.06 [-0.66, 0.55]Shuai Zheng (2017)0.640.04170.570.04172.2%1.71 [0.91, 2.61]Sophie Cassidy (2019)3.871.6113.931.6112.0%-0.04 [-0.87, 0.80]Stela V. Philbois (2022)3.762.63253.822.89254.3%-0.02 [-0.58, 0.53]Stephen H. Boutcher (2013)3.522.74163.72.91162.9%-0.06 [-0.76, 0.63]Steve E. Selig, Phd (2003)3.972.68184.12.47183.2%-0.13 [-0.78, 0.53]Wan-An Lu (2011)3.31.17253.441.18254.3%-0.02 [-0.39, 0.34]Wei Zhou	1%     0.01 [-0.40, 0.42]       1%     -0.05 [-1.18, 1.08]       9%     -0.17 [-0.70, 0.35]       3%     0.04 [-0.82, 0.90]       1%     -0.02 [-0.25, 0.30]       1%     -0.02 [-0.64, 0.60]       1%     -0.02 [-0.64, 0.60]       2%     1.71 [0.91, 2.51]       1%     -0.02 [-0.58, 0.53]       3%     -0.02 [-0.58, 0.53]       1%     -0.04 [-0.67, 0.59]       1%     -0.04 [-0.67, 0.59]       1%     -0.02 [-0.58, 0.53]       1%     -0.13 [-0.78, 0.53]       1%     -0.02 [-0.63, 0.34]
Patricia Concepción García-Suáre(2022)3.942.5564.093.0261.1% $-0.05$ [-1.18, 1.08]Pooja Bhati (2023)7.133.13287.693.35284.7% $-0.17$ [ $-0.70$ , 0.35]Preeyaphorn Songsorn(2021)3.493.19103.362.98111.9% $0.04$ [ $-0.25$ , 0.30]Salene M.W. Jones(2016)4.132.881004.062.9710012.4% $0.02$ [ $-0.25$ , 0.30]Sascha Ketelhut (2024)6.743.13206.912.83203.5% $-0.02$ [ $-0.64$ , 0.60]Shirley Telles (2016)3.922.48214.072.62213.7% $-0.06$ [ $-0.66$ , 0.55]Shuai Zheng (2017)0.640.04170.570.04172.2%1.71 [ $0.91$ , 2.51]Sophie Cassidy (2019)3.871.6113.931.6112.0% $-0.04$ [ $-0.87$ , 0.60]Stella V. Philbois (2022)3.762.63253.822.89254.3% $-0.02$ [ $-0.56$ , 0.53]Steve E. Selig, Phd (2003)3.972.69194.082.9% $-0.04$ [ $-0.87$ , 0.63]Steve E. Selig, Phd (2013)3.522.74163.72.91162.9% $-0.04$ [ $-0.76$ , 0.63]Steve E. Selig, Phd (2003)3.972.69194.082.95203.4% $-0.02$ [ $-0.67$ , 0.44]Wei Zhou (2017)4.211.74574.251.58578.4% $-0.02$ [ $-0.36$ ,	1%     -0.05 [-1.18, 1.08]       7%     -0.17 [-0.70, 0.35]       3%     0.04 [-0.82, 0.90]       3%     0.02 [-0.25, 0.30]       5%     -0.02 [-0.64, 0.60]       7%     -0.06 [-0.66, 0.55]       2%     1.71 [0.91, 2.51]       3%     -0.04 [-0.87, 0.80]       3%     -0.04 [-0.87, 0.63]       3%     -0.04 [-0.67, 0.53]       3%     -0.04 [-0.70, 0.53]       3%     -0.13 [-0.70, 0.53]       3%     -0.02 [-0.39, 0.34]
Pooja Bhati (2023)7.133.13287.693.35284.7% $-0.17 [-0.70, 0.36]$ Preeyaphorn Songsom(2021)3.493.19103.362.88111.9% $0.04 [-0.22, 0.90]$ Salene M.W. Jones (2016)4.132.881004.062.9710012.4% $0.02 [-0.25, 0.30]$ Sascha Ketelhut (2024)6.743.13206.912.83203.5% $-0.02 [-0.64, 0.60]$ Shirley Telles (2016)3.922.48214.072.82213.7% $-0.06 [-0.66, 0.55]$ Shuai Zheng (2017)0.640.04170.570.04172.2%1.71 [0.91, 2.51]Sophie Cassidy (2019)3.871.6113.391.6112.0% $-0.04 [-0.87, 0.80]$ Stella V. Philbois (2022)3.762.63253.822.89254.3% $-0.02 [-0.58, 0.53]$ Steve E. Selig, Phd (2003)3.972.69194.082.85203.4% $-0.04 [-0.67, 0.69]$ Tseng-Hau Tseng (2017)3.762.68184.12.47183.2% $-0.13 [-0.78, 0.63]$ Wan-An Lu (2011)3.31.17253.441.18254.3% $-0.02 [-0.67, 0.44]$ Wei Zhou (2017)4.211.74574.251.58578.4% $-0.02 [-0.38, 0.34]$ Test for overall effect Z = 0.53 (P = 0.60)Fi	7%     -0.17 [-0.70, 0.35]       9%     0.04 [-0.82, 0.90]       1%     0.02 [-0.25, 0.30]       7%     -0.02 [-0.64, 0.60]       7%     -0.06 [-0.66, 0.55]       1%     0.02 [-0.58, 0.63]       9%     -0.02 [-0.68, 0.53]       9%     -0.02 [-0.68, 0.53]       9%     -0.02 [-0.68, 0.53]       9%     -0.04 [-0.87, 0.69]       9%     -0.13 [-0.78, 0.53]       1%     -0.12 [-0.70, 0.41]       9%     -0.02 [-0.39, 0.34]
Preeyaphom Songsom(2021)3.493.19103.362.98111.9% $0.04$ [-0.82, 0.90]Salene M.W. Jones(2016)4.132.881004.062.9710012.4% $0.02$ [-0.54, 0.60]Sascha Ketelhut (2024)6.743.13206.912.83203.5% $-0.02$ [-0.64, 0.60]Shirley Telles (2016)3.922.48214.072.82213.7% $-0.06$ [-0.66, 0.65]Shirley Telles (2017)0.640.04170.570.04172.2%1.71 [0.91, 2.51]Sophie Cassidy (2019)3.871.6113.931.6112.0% $-0.04$ [-0.87, 0.80]Stella V. Philbois (2022)3.762.63253.822.89254.3% $-0.02$ [-0.58, 0.53]Stephen H. Boutcher (2013)3.522.74163.72.91162.9% $-0.06$ [-0.76, 0.63]Steve E. Selig, Phd (2003)3.972.68184.12.47183.2% $-0.13$ [-0.78, 0.53]Swan-An Lu (2011)3.31.17253.441.18254.3% $-0.12$ [-0.67, 0.44]Wei Zhou (2017)4.211.74574.251.58578.4% $-0.02$ [-0.39, 0.34]Total (95% CI)625629100.0% $-0.03$ [-0.16, 0.09]Testfor overall effect: Z = 0.53 (P = 0.60)Fi	3%       0.04 [-0.32, 0.90]         1%       0.02 [-0.25, 0.30]         5%       -0.02 [-0.26, 0.60]         7%       -0.06 [-0.66, 0.55]         2%       1.71 [0.91, 2.51]         1%       -0.02 [-0.58, 0.53]         3%       -0.02 [-0.58, 0.53]         1%       -0.04 [-0.87, 0.63]         1%       -0.04 [-0.67, 0.59]         2%       -0.13 [-0.78, 0.53]         1%       -0.02 [-0.38, 0.34]
Salene M.W. Jones (2016)       4.13       2.88       100       4.06       2.97       100       12.4%       0.02 [-0.25, 0.30]         Sascha Ketelhut (2024)       6.74       3.13       20       6.9       12.83       20       3.5%       -0.02 [-0.64, 0.60]         Shirley Telles (2016)       3.92       2.48       21       4.07       2.82       21       3.7%       -0.06 [-0.66, 0.55]         Shuai Zheng (2017)       0.64       0.40       17       0.57       0.04       17       2.2%       1.71 [0.91, 2.61]         Sophie Cassidy (2019)       3.87       1.6       11       3.93       1.6       11       2.0%       -0.04 [-0.87, 0.80]         Stella V. Philbois (2022)       3.76       2.63       25       3.82       2.89       25       4.3%       -0.02 [-0.58, 0.53]         Stephen H. Boutcher (2013)       3.52       2.74       16       3.76       2.68       16       2.9%       -0.06 [-0.76, 0.63]         Steve E. Selig, Phd (2003)       3.97       2.68       18       4.1       2.47       18       3.2%       -0.13 [-0.78, 0.53]         Wan-An Lu (2011)       3.3       1.17       25       3.44       1.18       25       4.3%       -0.12 [-0.67, 0.44]<	4%       0.02 [-0.25, 0.30]         5%       -0.02 [-0.64, 0.60]         7%       -0.06 [-0.66, 0.55]         2%       1.71 [0.91, 2.51]         3%       -0.02 [-0.58, 0.53]         3%       -0.02 [-0.67, 0.63]         4%       -0.04 [-0.67, 0.63]         3%       -0.02 [-0.76, 0.63]         4%       -0.04 [-0.67, 0.59]         2%       -0.13 [-0.78, 0.53]         3%       -0.02 [-0.39, 0.34]
Sascha Ketelhut (2024) $6.74$ $3.13$ $20$ $6.9$ $12.83$ $20$ $3.5\%$ $-0.02$ [- $0.64$ , $0.60$ ]         Shirley Telles (2016) $3.92$ $2.48$ $21$ $4.07$ $2.82$ $21$ $3.7\%$ $-0.06$ [ $-0.66$ , $0.65$ ]         Shuai Zheng (2017) $0.64$ $0.04$ $17$ $0.57$ $0.04$ $17$ $2.2\%$ $1.71$ [ $0.91$ , $2.51$ ]         Sophic Cassidy (2019) $3.87$ $1.6$ $11$ $3.93$ $1.6$ $11$ $2.0\%$ $-0.04$ [ $-0.87$ , $0.80$ ]         Stella V. Philbois (2022) $3.76$ $2.63$ $25$ $3.82$ $2.89$ $25$ $4.3\%$ $-0.02$ [ $-0.58$ , $0.53$ ]         Stephen H. Boutcher (2013) $3.52$ $2.74$ $16$ $3.7$ $2.91$ $16$ $2.9\%$ $-0.04$ [ $-0.87$ , $0.63$ ]         Steve E. Selig, Phd (2003) $3.97$ $2.68$ $18$ $4.1$ $2.47$ $18$ $3.2\%$ $-0.13$ [ $-0.78$ , $0.53$ ]         Steve E. Selig, Phd (2003) $3.97$ $2.68$ $18$ $4.1$ $2.47$ $18$ $3.2\%$ $-0.13$ [ $-0.78$ , $0.53$ ]         War-An Lu (2011)	5%       -0.02 [-0.64, 0.60]         7%       -0.06 [-0.66, 0.55]         2%       1.71 [0.91, 2.51]         3%       -0.04 [-0.87, 0.80]         3%       -0.06 [-0.76, 0.63]         3%       -0.04 [-0.87, 0.59]         2%       -0.13 [-0.78, 0.53]         3%       -0.04 [-0.87, 0.44]         1%       -0.02 [-0.39, 0.34]
Shirley Telles (2016)       3.92       2.48       21       4.07       2.82       21       3.7%       -0.06 [-0.66, 0.55]         Shuai Zheng (2017)       0.64       0.04       17       0.57       0.04       17       2.2%       1.71 [0.91, 2.51]         Sophie Cassidy (2019)       3.87       1.6       11       3.93       1.6       11       2.2%       1.71 [0.91, 2.51]         Stella V. Philbois (2022)       3.76       2.63       25       3.82       2.89       25       4.3%       -0.02 [-0.58, 0.53]         Stephen H. Boutcher (2013)       3.52       2.74       16       3.7       2.91       16       2.9%       -0.04 [-0.76, 0.63]         Stepke T. Boutcher (2013)       3.52       2.74       16       3.7       2.91       16       2.9%       -0.04 [-0.76, 0.63]         Steve E. Selig, Phd (2003)       3.97       2.69       19       4.08       2.85       20       3.4%       -0.04 [-0.67, 0.59]       Tseng-Hau Tseng (2017)       3.76       2.68       18       4.1       2.47       18       3.2%       -0.13 [-0.78, 0.53]       Wan-An Lu (2011)       3.3       1.17       25       3.44       1.18       25       4.3%       -0.02 [-0.39, 0.34]       10.04       10.04<	7%     -0.06 [-0.66, 0.55]       2%     1.71 [0.91, 2.51]       3%     -0.02 [-0.58, 0.63]       3%     -0.02 [-0.58, 0.63]       3%     -0.04 [-0.67, 0.59]       2%     -0.13 [-0.77, 0.59]       2%     -0.12 [-0.67, 0.44]       1%     -0.02 [-0.39, 0.34]
Shuai Zheng (2017)       0.64       0.04       17       0.57       0.04       17       2.2%       1.71 [0.91, 2.51]         Sophie Cassidy (2019)       3.87       1.6       11       3.93       1.6       11       2.0%       -0.04 [-0.87, 0.80]         Stella V. Philbois (2022)       3.76       2.63       25       3.80       -0.02 [-0.58, 0.53]         Stephen H. Boutcher (2013)       3.52       2.74       16       3.7       2.91       16       2.9%       -0.04 [-0.87, 0.63]         Steve E. Selig, Phd (2003)       3.97       2.68       19       4.08       2.85       20       3.4%       -0.04 [-0.67, 0.63]         Steve E. Selig, Phd (2003)       3.97       2.68       18       4.1       2.47       18       3.2%       -0.13 [-0.78, 0.53]         Tseng-Hau Tseng (2017)       3.76       2.68       18       4.1       2.47       18       3.2%       -0.12 [-0.67, 0.44]         Wei Zhou (2017)       4.21       1.74       57       4.25       1.58       57       8.4%       -0.02 [-0.39, 0.34]         Total (95% Cl)       625       629       100.0%       -0.03 [-0.16, 0.09]	2%       1.71 [0.91, 2.51]         0%       -0.04 [-0.87, 0.80]         3%       -0.02 [-0.58, 0.53]         3%       -0.06 [-0.76, 0.63]         1%       -0.04 [-0.87, 0.59]         2%       -0.13 [-0.78, 0.53]         3%       -0.12 [-0.67, 0.44]         1%       -0.02 [-0.39, 0.34]
Sophie Cassidy (2019)       3.87       1.6       11       3.93       1.6       11       2.0% $-0.04$ [-0.87, 0.80]         Stella V. Philbois (2022)       3.76       2.63       25       3.82       2.89       25       4.3% $-0.02$ [-0.58, 0.53]         Stephen H. Boutcher (2013)       3.52       2.74       16       3.7       2.91       16       2.9% $-0.06$ [-0.76, 0.63]         Steve E. Selig, Phd (2003)       3.97       2.68       19       4.08       2.85       20       3.4% $-0.04$ [-0.67, 0.59]         Tseng-Hau Tseng (2017)       3.76       2.68       18       4.1       2.47       18       3.2% $-0.13$ [-0.78, 0.53]         Wan-An Lu (2011)       3.3       1.17       25       3.44       1.18       25       4.3% $-0.12$ [-0.67, 0.44]         Wei Zhou (2017)       4.21       1.74       57       4.25       1.58       57       8.4% $-0.02$ [-0.39, 0.34]         Total (95% CI)       625       629       100.0% $-0.03$ [-0.16, 0.09]	0%     -0.04 [-0.87, 0.80]       3%     -0.02 [-0.58, 0.53]       9%     -0.06 [-0.76, 0.63]       1%     -0.04 [-0.67, 0.59]       2%     -0.13 [-0.78, 0.53]       3%     -0.12 [-0.67, 0.44]       1%     -0.02 [-0.39, 0.34]
Stella V. Philbois (2022)       3.76       2.63       25       3.82       2.89       25       4.3%       -0.02 [-0.58, 0.53]         Stephen H. Boutcher (2013)       3.52       2.74       16       3.7       2.91       16       2.9%       -0.06 [-0.76, 0.63]         Steve E. Selig, Phd (2003)       3.97       2.69       19       4.08       2.85       20       3.4%       -0.04 [-0.67, 0.59]         Tseng-Hau Tseng (2017)       3.76       2.68       18       4.1       2.47       18       3.2%       -0.13 [-0.78, 0.53]         Wan-An Lu (2011)       3.3       1.17       25       3.44       1.18       25       4.3%       -0.12 [-0.67, 0.44]         Wei Zhou (2017)       4.21       1.74       57       4.25       1.58       57       8.4%       -0.02 [-0.38, 0.34]         Total (95% Cl)       625       629       100.0%       -0.03 [-0.16, 0.09]	3%     -0.02 [-0.58] 0.53]       3%     -0.06 [-0.76] 0.63]       1%     -0.04 [-0.67] 0.59]       2%     -0.13 [-0.78] 0.53]       3%     -0.12 [-0.67] 0.64]       1%     -0.02 [-0.39] 0.34]
Stephen H. Boutcher (2013) $3.52$ $2.74$ $16$ $3.7$ $2.91$ $16$ $2.9\%$ $-0.06$ [-0.76, 0.63]         Steve E. Selig, Phd (2003) $3.97$ $2.69$ $19$ $4.08$ $2.85$ $20$ $3.4\%$ $-0.04$ [-0.67, 0.59]         Tseng-Hau Tseng (2017) $3.76$ $2.68$ $18$ $4.1$ $2.47$ $18$ $3.2\%$ $-0.13$ [ $-0.78$ , 0.63]         Wan-An Lu (2011) $3.3$ $1.17$ $25$ $3.44$ $1.18$ $25$ $4.3\%$ $-0.12$ [ $-0.67$ , 0.44]         Wei Zhou (2017) $4.21$ $1.74$ $57$ $4.25$ $1.58$ $57$ $8.4\%$ $-0.02$ [ $-0.39$ , 0.34]         Total (95% CI)       625       629       100.0\% $-0.03$ [ $-0.16$ , 0.09]	9%     -0.06 [-0.76] 0.63]       1%     -0.04 [-0.67] 0.59]       2%     -0.13 [-0.78] 0.53]       3%     -0.12 [-0.67] 0.44]       4%     -0.02 [-0.39] 0.34]
Steve E. Selig, Phd (2003)       3.97       2.69       19       4.08       2.85       20       3.4%       -0.04 [-0.67, 0.59]         Tseng-Hau Tseng (2017)       3.76       2.68       18       4.1       2.47       18       3.2%       -0.13 [-0.78, 0.53]         Wan-An Lu (2011)       3.3       1.17       25       3.44       1.18       25       4.3%       -0.12 [-0.67, 0.44]         Wei Zhou (2017)       4.21       1.74       57       4.25       1.58       57       8.4%       -0.02 [-0.39, 0.34]         Total (95% Cl)       625       629       100.0%       -0.03 [-0.16, 0.09]	4%     -0.04 [-0.67, 0.59]       2%     -0.13 [-0.78, 0.53]       3%     -0.12 [-0.67, 0.44]       1%     -0.02 [-0.39, 0.34]
Tseng-Hau Tseng (2017)       3.76       2.68       18       4.1       2.47       18       3.2%       -0.13 [-0.78, 0.53]         Wan-An Lu (2011)       3.3       1.17       25       3.44       1.18       25       4.3%       -0.12 [-0.67, 0.44]         Wei Zhou (2017)       4.21       1.74       57       4.25       1.58       57       8.4%       -0.02 [-0.39, 0.34]         Total (95% Cl)       625       629       100.0%       -0.03 [-0.16, 0.09]	2%     -0.13 [-0.78, 0.53]       3%     -0.12 [-0.67, 0.44]       1%     -0.02 [-0.39, 0.34]
Wan-An Lu (2011)       3.3       1.17       25       3.44       1.18       25       4.3%       -0.12 [-0.67, 0.44]         Wei Zhou (2017)       4.21       1.74       57       4.25       1.58       57       8.4%       -0.02 [-0.39, 0.34]         Total (95% Cl)       625       629       100.0%       -0.03 [-0.16, 0.09]	3% -0.12 [-0.67, 0.44] 4% -0.02 [-0.39, 0.34]
Wei Zhou (2017)       4.21       1.74       57       4.25       1.58       57       8.4%       -0.02 [-0.39, 0.34]         Total (95% CI)       625       629       100.0%       -0.03 [-0.16, 0.09]         Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 28.35, df = 25 (P = 0.29); I <sup>2</sup> = 12%       Test for overall effect: Z = 0.53 (P = 0.60)       F(3)	1% -0.02 [-0.39, 0.34]
Total (95% Cl)         625         629         100.0%         -0.03 [-0.16, 0.09]           Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 28.35, df = 25 (P = 0.29); I <sup>2</sup> = 12%         Test for overall effect: Z = 0.53 (P = 0.60)         Fille	
Total (95% Cl)         625         629         100.0%         -0.03 [-0.16, 0.09]           Heterogeneity:         Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 28.35, df = 25 (P = 0.29); I <sup>2</sup> = 12%         Test for overall effect: Z = 0.53 (P = 0.60)         Fille	
Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 28.35, df = 25 (P = 0.29); l <sup>2</sup> = 12% Test for overall effect: Z = 0.53 (P = 0.60)	J% -0.03 I-0.10, 0.091
Test for overall effect: $Z = 0.53$ (P = 0.60) Fi	
Fig. 2000 ( - 0.00)	-2 -1 0 1 2
	Favours [experimental] Favours [control]

borghi-silva (2015)	weatt	SD	Total	Mean	SD	Total	Weight	IV. Random, 95% CI	IV. Random, 95% CI
	0.5	0.24	10	0.58	0.23	10	2.3%	-0.33 [-1.21, 0.56]	
. M. Gerage (2012)	3.58	2.91	15	3.46	2.74	14	3.1%	0.04 [-0.69, 0.77]	
nneke van Bilion (2018)	4.1	0.26	30	3.98	0.49	30	5.0%	0.30 (-0.21, 0.81)	
andi Hari Krishna (2014)	4.24	2.13	44	3.89	2.24	48	6.2%	0.16 [-0.25, 0.57]	
runa Gallo-Silva (2019)	3.79	2.38	10	3.39	2.6	9	2.3%	0.15 (-0.75, 1.06)	<u> </u>
iordie G. Jakovlevic (2013)	0.4	0.1	9	1.19	0.64	8	1.5%	-1.69 [-2.84, -0.54]	
anagarajan Inbaraj (2023)	7.74	3.62	29	4.97	2.57	30	4.7%	0.87 [0.34, 1.41]	
élcio Kanegusuku, PhD (2017)	3.63	1.6	15	3.4	1.09	15	3.2%	0.16 [-0.55, 0.88]	_ <del></del>
Hua Chu(2015)	3.94	2.73	26	3.94	2.71	26	4.6%	0.00 [-0.54, 0.54]	
Hua Chu(2016)	4.09	2.61	13	3.79	3.03	13	2.9%	0.10 [-0.67, 0.87]	
ellie Toohey (2020)	5.5	3.13	6	3.83	0.75	6	1.5%	0.68 [-0.50, 1.86]	
aharana Satyapriya(2008)	3.31	1.78	45	3.37	2	45	6.1%	-0.03 [-0.44, 0.38]	-
atricia Concepción García-Suáre(2022)	3.87	2.55	6	3.68	3.02	6	1.6%	0.06 [-1.07, 1.19]	
ooja Bhati (2023)	7	3.13	28	6.43	3.39	28	4.8%	0.17 [-0.35, 0.70]	
reeyaphorn Songsorn(2021)	4.19	3.18	10	4.26	2.97	11	2.5%	-0.02 [-0.88, 0.83]	
alene M.W. Jones(2016)	3.61	2.88	100	3.72	2.97	100	8.1%	-0.04 [-0.31, 0.24]	+
ascha Ketelhut (2024)	6.59	3.35	20	6.5	3.91	20	3.9%	0.02 [-0.60, 0.64]	
hirley Telles (2016)	3.89	2.48	21	3.72	2.82	21	4.0%	0.06 [-0.54, 0.67]	
huai Zheng (2017)	0.36	0.04	17	0.43	0.04	17	2.7%	-1.71 [-2.51, -0.91]	
ophie Cassidy (2019)	3.95	1.6	11	3.89	1.6	11	2.6%	0.04 [-0.80, 0.87]	
tella V. Philbois (2022)	4.04	2.63	25	3.98	2.89	25	4.5%	0.02 [-0.53, 0.58]	
tephen H. Boutcher (2013)	4.19	2.74	16	4.08	2.91	16	3.4%	0.04 [-0.66, 0.73]	
teve E. Selig, Phd (2003)	3.7	2.64	19	3.53	2.8	20	3.8%	0.06 [-0.57, 0.69]	_ <del></del>
seng-Hau Tseng (2017)	3.88	2.61	18	3.51	2.42	18	3.6%	0.14 [-0.51, 0.80]	
/an-An Lu (2011)	3.67	2.18	25	3.79	1.2	25	4.5%	-0.07 [-0.62, 0.49]	
/ei Zhou (2017)	3.47	1.74	57	3.37	1.59	57	6.7%	0.06 [-0.31, 0.43]	+
otal (95% CI)			625			629	100.0%	0.03 [-0.12, 0.18]	•
eterogeneity: Tau <sup>2</sup> = 0.05; Chi <sup>2</sup> = 40.65, d	f= 25 (P	= 0.02	); <b>Iz</b> = 3	9%				-	
est for overall effect: Z = 0.35 (P = 0.72)									Favours [experimental] Favours [control]
									r avours [experimental] - r avours [control]
JRE 7									

Study or Subaroup	Mean	SD	Total	Mean	SD	Total	Weight	IV. Random, 95% Cl	IV. Random, 95% Cl
A borghi-silva (2015)	1.77	1.74	10	2.3	1.8	10	3.5%	-0.29 [-1.17, 0.60]	
M Gerage (2012)	3.17	3.6	15	3.11	2.2	14	3.9%	0.02 [-0.71, 0.75]	<u> </u>
Nireza Ghardashi-Afousi (2018)	1.72	0.89	14	2.39	1.2	14	3.8%	-0.62 [-1.38, 0.15]	
Anneke van Bilion (2018)	0.57	2.56	29	0.51	2.05	24	4.4%	0.031-0.52.0.571	
Bandi Hari Krishna (2014)	0.45	0.16	44	1.19	0.86	48	4.6%	-1.16 [-1.61, -0.72]	
Birinder S Cheema(2013)	2.24	2.69	18	1.1	2.4	19	4.1%	0.44 (-0.21, 1.09)	
Bruna Gallo-Silva (2019)	2.1	1	10	3.4	1.9	9	3.3%	-0.83 [-1.78, 0.12]	
Diordie G. Jakovlevic (2013)	1.5	1.1	9	3.3	1.9	8	3.1%	-1.12 [-2.16, -0.07]	
Janagarajan Inbaraj (2023)	0.6	0.4	29	3.1	1	30	3.7%	-3.22 [-4.01, -2.43]	
Hélcio Kanegusuku, PhD (2017)	1.7	0.6	15	2.5	0.4	15	3.6%	-1.53 [-2.35, -0.70]	
-Hua Chu(2015)	1.05	0.82	26	0.89	0.53	26	4.4%	0.23 [-0.32, 0.77]	
-Hua Chu(2016)	0.67	0.63	13	1.8	1.59	13	3.7%	-0.90 [-1.72, -0.09]	
lesús Alarcón-Gómez(2021)	1.9	2.2	11	1.5	0.9	8	3.4%	0.21 [-0.70, 1.13]	
<aravirta (2013)<="" td=""><td>1.27</td><td>1.25</td><td>26</td><td>1.67</td><td>1.73</td><td>17</td><td>4.2%</td><td>-0.27 [-0.88, 0.34]</td><td></td></aravirta>	1.27	1.25	26	1.67	1.73	17	4.2%	-0.27 [-0.88, 0.34]	
(ellie Toohey (2020)	0.73	1.73	6	1.11	1.8	6	2.9%	-0.20 [-1.33, 0.94]	
Maharana Satyapriya(2008)	2.79	0.75	45	2.64	0.9	45	4.7%	0.18 [-0.23, 0.59]	
Patricia Concepción García-Suáre(2022)	1.22	0.72	6	2.42	2.2	6	2.8%	-0.68 [-1.86, 0.50]	
Pooja Bhati (2023)	1.15	0.41	28	1.25	0.33	28	4.4%	-0.26 [-0.79, 0.26]	
Preeyaphorn Songsorn(2021)	1.38	3.08	10	0.65	0.82	11	3.6%	0.32 [-0.54, 1.18]	<del></del>
Ran L(2022)	1.3	1.1	13	3.2	2.8	14	3.7%	-0.85 [-1.65, -0.06]	
Sascha Ketelhut (2024)	1.14	0.46	20	1.4	0.84	20	4.2%	-0.38 [-1.00, 0.25]	
Shirley Telles (2016)	1.15	0.53	21	1.94	1.53	21	4.2%	-0.68 [-1.30, -0.05]	
Sophie Cassidy (2019)	0.73	0.07	11	1	0.17	11	3.1%	-2.00 [-3.06, -0.94]	
Stella V. Philbois (2022)	0.89	0.53	21	0.99	0.57	25	4.3%	-0.18 [-0.76, 0.40]	
Steve E. Selig, Phd (2003)	1.68	1.25	19	2.66	2.57	20	4.2%	-0.47 [-1.11, 0.17]	
Tseng-Hau Tseng (2017)	1.06	0.68	18	1.83	1.6	18	4.1%	-0.61 [-1.28, 0.06]	
Fotal (95% CI)			487			480	100.0%	-0.54 [-0.83, -0.25]	•
Heterogeneity: Tau <sup>2</sup> = 0.41; Chi <sup>2</sup> = 111.00.	df = 25 (l	P < 0.0	0001);	l <sup>2</sup> = 779	6				
									-4 -2 U 2 4

study results showed that the exercise intervention had a significant effect on the LF/HF ratio in the mixed-gender group, but the effect was not statistically significant in the female group.

A total of 20 studies were included in the subgroup analysis of BMI effects on LF/HF. In the normal group, SMD = -0.37 (95% CI: -0.75 to 0.01, P = 0.06,  $I^2 = 46\%$ ). In the overweight group, SMD = -0.63 (95% CI: -1.26 to 0.00, P = 0.05,  $I^2 = 88\%$ ). In the obese group, SMD = -0.95 (95% CI: -1.74 to -0.15, P = 0.02,  $I^2 = 67\%$ ). The study results showed that the exercise intervention had a significant effect on the LF/HF ratio in the obesity group, but did not demonstrate significant effects in the normal weight and overweight groups.

A total of 22 studies were included in the subgroup analysis of regional effects on LF/HF. In South America, SMD = -0.52 (95% CI: -1.07 to 0.02, P = 0.06). In Asia, SMD = -0.62 (95% CI: -1.18 to -0.06, P = 0.03). In North America, SMD = -1.10 (95% CI: -1.52 to -0.69, P < 0.001). In Europe, SMD = -0.63 (95% CI: -1.27 to 0.00, P = 0.05). In Oceania, SMD = -0.06 (95% CI: -0.68 to 0.56, P = 0.85). The study results showed that the exercise intervention had statistically significant effects in the Asian and North American subgroups, but did not reach statistical significance in the South American, Oceania, and European subgroups.

#### 3.5.2 Intervention characteristics

A total of 25 studies were included in the subgroup analysis of training methods on LF/HF. For HIIT, SMD = -0.36 (95% CI: -0.80 to 0.09, P = 0.11,  $I^2 = 55\%$ ). For aerobic training, SMD = -0.57 (95% CI: -1.04 to -0.11, P = 0.02,  $I^2 = 0\%$ ). For resistance training, SMD = -0.56 (95% CI: -0.93 to -0.19,

P = 0.003). For mind-body training, SMD = -0.71 (95% CI: -1.50 to 0.09, P = 0.08,  $I^2 = 93\%$ ). The study results indicated that compared to the control group, High-Intensity Interval Training (HIIT) and mind-body interventions did not show significant effects. In contrast, aerobic training and resistance training demonstrated positive intervention outcomes.

A total of 26 studies were included in the subgroup analysis of intervention duration on LF/HF. For interventions  $\geq 8$  weeks, SMD = -0.63 (95% CI: -0.96 to -0.31, P < 0.001,  $I^2 = 79\%$ ). For interventions <8 weeks, SMD = -0.04 (95% CI: -0.42 to 0.34, P = 0.84,  $I^2 = 7\%$ ). The study results indicate that, compared to the control group, exercise interventions lasting  $\geq 8$  weeks significantly influenced the LF/HF ratio, whereas interventions lasting <8 weeks showed no significant effect. The between-group comparison yielded a *p*-value of 0.02; however, due to partial overlap in the confidence intervals, the results should be interpreted with caution.

A total of 26 studies were included in the subgroup analysis of intervention frequency on LF/HF. For interventions  $\geq 3$  times/ week, SMD = -0.52 (95% CI: -0.90 to -0.15, P = 0.006,  $I^2 = 81\%$ ). For interventions <3 times/week, SMD = -0.57 (95% CI: -0.98 to -0.16, P = 0.007,  $I^2 = 61\%$ ). The study results indicate that, compared to the control group, exercise interventions with frequencies of  $\geq 3$  times per week and <3 times per week both significantly influenced the LF/HF ratio. The between-group comparison yielded a *p*-value of 0.39, suggesting that the differences in the effects of intervention frequency on the LF/HF ratio were not statistically significant.

A total of 26 studies were included for subgroup analysis against control groups. For the intervention group compared to

Subgroup	Group	Std	Mean Difference (IV, Random, 95% CI)	<i>p</i> -value	Heterogeneity (/ <sup>2</sup> %)	Between- group <i>p</i> -value	Between-group heterogeneity (1 <sup>2</sup> %)			
Individual factors										
Age group	24	-0.58	[-0.89,-0.26]			0.94	0%			
18-65 years	19	-0.57	[-0.94,-0.20]	0.003	82%					
>65 years	5	-0.60	[-1.11,-0.08]	0.02	53%					
Health status	26	-0.54	[-0.83,-0.25]			0.004	87.8%			
Healthy	12	-0.14	[-0.38,0.11]	0.27	39%					
Disease	14	-0.87	[-1.31,-0.43]	< 0.001	80%					
Gender	24	-0.53	[-0.83,-0.22]			0.90	0%			
Female only	9	-0.56	[-1.19,0.08]	0.09 88%						
Mixed gender	15	-0.60	[-1.11,-0.08]	0.002	67%					
BMI	20	-0.61	[-0.97,-0.26]			0.40	0%			
Normal	6	-0.37	[-0.75,0.01]	0.06	46%					
Overweight	10	-0.63	[-1.26,-0.00]	0.05	88%					
Obese	4	-0.95	[-1.74,-0.15]	0.02	67%					
Region	25	-0.57	[-0.87,-0.27]			0.08	51.3%			
South America	5	-0.52	[-1.07,0.02]	0.06	59%					
Asia	10	-0.62	[-1.18,-0.06]	0.03	87%					
North America	2	-1.10	[-1.52,0.69]	< 0.001	0%					
Europe	5	-0.63	[-1.27,0.00]	0.05	67%					
Oceania	3	-0.06	[-0.68,0.56]	0.85	49%					
Study design										
Intervention content	25	-0.56	[-0.86,-0.26]			0.84	0%			
HIIT	8	-0.36	[-0.80,0.09]	0.11	55%					
Aerobic training	3	-0.57	[-1.04,-0.11]	0.02	0%					
Resistance training	7	-0.56	[-0.93,-0.19]	0.003	47%					
Mind-body training	7	-0.71	[-1.50,0.09]	0.08	93%					
Intervention duration	26	-0.54	[0.83,-0.25]			0.02	81.9%			
≥8 weeks	22	-0.63	[-0.96,-0.31]	< 0.001	79%					
<8 weeks	4	-0.04	[-0.42,0.34]	0.84	7%					
Intervention frequency	26	-0.54	[-0.83,-0.25]			0.39	0%			
≥3 times/week	19	-0.52	[-0.90,-0.15]	0.006	81%					
<3 times/week	7	-0.57	[-0.98,-0.16]	0.007	61%					
Control group	26	-0.54	[-0.83,-0.25]			0.008	86%			
No exercise interventions	23	-0.61	[-0.93,-0.29]	<0.001	78%					
Low-intensity activities	3	0.01	[-0.32,0.33]	0.97	5%					

#### TABLE 4 Subgroup analysis results.

the "No Exercise Interventions" control group, the standardized mean difference (SMD) was -0.61 (95% CI: -0.93 to -0.29, P < 0.001,  $I^2 = 78\%$ ). For the intervention group compared to the "low-intensity activities" control group, the SMD was 0.01 (95% CI: -0.32 to 0.33, P = 0.97,  $I^2 = 5\%$ ). The results indicate that the effect of exercise intervention on the LF/HF ratio was significantly more pronounced compared to the "No Exercise Interventions" control group. However, no significant effect was observed when compared to the "low-intensity activities" control group. Although the between-group comparison yielded a *p*-value of 0.008, the partial overlap in the confidence intervals suggests that the results should be interpreted with caution

# 3.6 Sensitivity analysis

Sensitivity analysis was conducted for the five HRV indices (RMSSD, SDNN, LF, HF, LF/HF) (Figures 9–13). The analysis

showed that after sequentially excluding each study, the combined effect size estimates of the remaining studies all fell within the 95% confidence interval of the overall combined effect size. This finding indicates that the exclusion of any single study does not significantly alter the overall conclusions, thus confirming the robustness of the results for these five HRV indices. The sensitivity analysis charts for each index are as follows:

# 3.7 Publication bias

Funnel plots (Figures 14–18) were used to analyze the relationship between the standard error (s.e.) of SMD and SMD for different HRV outcomes, to assess the potential for publication bias. Ideally, study points should be evenly distributed around the central axis of the funnel plot, forming a symmetrical inverted funnel shape. However, the observed



			L		
A. borgni-silva(2015)			)		
A. M. Gerage (2012)					
Allieza Ghardashi-Alousi (2016)			J		
Aillieke vall Biljoll (2018) Birinder S. Cheema (2013)		0			
Binnder 5 Cheema(2013) Biako E. G. Colling (2023)			0		
Brupa Gallo-Silva (2019)			5	1	
Ganagarajan Inbaraj (2013)		0		1	
Gianluca Vernillo (2015)			· · · · · · · · · · · · · · · · · · ·		
Jesús Alarcón-Gómez(2021)			- 		
Kellie Toohey (2020)			<u></u>		
Patricia Concepción García-Suáre(2022)					
Pooia Bhati (2023)			r )		
Preevaphorn Songsorn(2021)					
Ran L(2022)			5		
Salene M.W. Jones (2016)					
Sascha Ketelhut (2024)			D		
Shirley Telles (2016)				4	
Stefano Benítez-Flores (2019)				1	
Stella V. Philbois (2022)			b		
Steve E. Selig, Phd (2003)		(	b		
			00	0.00	0.00
-	0.10-0.04	F 0.	.09	0.23	0.36







distribution exhibited a certain degree of asymmetry, suggesting the potential presence of publication bias. To further quantitatively evaluate bias, Begg's and Egger's tests were performed.

According to the Begg's and Egger's test results, no evidence of publication bias was found in the analyses of SDNN, LF, and HF, indicating relatively robust results. For RMSSD and LF/HF, the *P*-values were close to the significance threshold of 0.05, suggesting weak statistical evidence of publication bias. Although the asymmetry of the funnel plots does not completely rule out publication bias, its impact on the overall findings appears minimal.

# 4 Discussion

The meta-analysis indicated that long-term exercise interventions significantly reduced the LF/HF ratio, highlighting exercise's positive regulatory effects on ANS balance. A reduction in LF/HF typically reflects either inhibition of sympathetic nervous activity and/or enhancement of parasympathetic nervous activity, both of which are crucial for cardiovascular and mental health (4, 55, 56). This finding aligns with previous research. For instance, Sandercock et al.'s meta-analysis on long-term interventions involving aerobic training, resistance training, and training showed that exercise combined interventions significantly improved frequency-domain heart rate variability (HRV) metrics, particularly the LF/HF ratio (12). Similarly, Shaffer and Ginsberg (2) noted that a reduction in LF/HF not only marks decreased sympathetic activity but may also reflect enhanced vagal activation, which is essential for lowering cardiovascular disease risk and improving mental health. Furthermore, Deng et al. (57) demonstrated that exercise interventions, especially in individuals with heightened sympathetic activity or cardiovascular diseases, significantly improved HRV indices by enhancing vagal tone and inhibiting sympathetic excitability.

Despite the overall significant effects, substantial heterogeneity was observed among the studies ( $I^2 = 77\%$ ). Therefore, this study further conducted subgroup and sensitivity analyses to explore potential sources of heterogeneity and examine the influence of different intervention types, participant characteristics, or study designs on the outcomes.

The study found that the effects of exercise interventions on LF/HF differed significantly between healthy and disease populations. Compared to the control group, the exercise intervention showed no significant effect in the healthy group, while it was markedly effective in the disease group. The between-group comparison yielded a *P*-value of 0.004, and the non-overlapping confidence intervals indicated a significant difference in intervention outcomes between the two groups. This suggests that the efficacy of exercise interventions in improving ANS function may depend on participants' baseline health status. Specifically, the pronounced improvement in the disease group may reflect more evident baseline autonomic dysfunction, such as excessive sympathetic activity or suppressed vagal tone. Exercise interventions effectively restored ANS











balance in the disease group by enhancing vagal tone, suppressing sympathetic excitability, and improving metabolic health (4). For example, individuals with cardiovascular diseases, diabetes, or obesity typically exhibit lower baseline HRV and higher LF/HF ratios, making them more responsive to exercise-induced improvements (12). Additionally, exercise interventions may further optimize ANS function in the disease group by reducing chronic inflammation, improving insulin sensitivity, and enhancing cardiovascular adaptability (58). In contrast, the lack of significant effects in the healthy group may reflect their relatively balanced ANS function at baseline. Healthy individuals generally exhibit higher HRV and lower LF/HF ratios, indicating a more balanced sympathetic-parasympathetic activity (59). Thus, the limited room for improvement in ANS function in the healthy group may explain the less pronounced effects of exercise interventions. Moreover, the already healthy lifestyle and exercise habits of this population may further constrain the additional benefits of interventions.

Although significant improvements in the LF/HF ratio were observed across different age groups, the between-group comparison yielded a *P*-value of 0.94, indicating no statistically significant difference in the effects of exercise on LF/HF across age groups. This suggests that long-term exercise interventions may have a universal effectiveness in improving ANS balance across ages. However, it is noteworthy that the heterogeneity was higher in the 18–65 age group ( $I^2 = 82\%$ ) compared to the over-65 age group ( $I^2 = 53\%$ ). This difference in heterogeneity may

reflect the diversity of participant characteristics and variability in intervention effects within different age groups. While exercise interventions were effective across age groups, the heterogeneity highlights the need for cautious interpretation of the results. For the 18–65 age group, future studies may need to refine subgroup analyses to explore the influence of participant characteristics (e.g., health status, exercise habits) on intervention outcomes. For the over-65 age group, despite lower heterogeneity, individual differences should still be considered, particularly when designing exercise interventions to ensure safety and efficacy in older adults (56).

In the mixed-gender subgroup, significant changes were observed (SMD = -0.51, 95% CI: -0.83 to -0.19, P = 0.002). However, in the female subgroup, the confidence interval included zero, indicating no significant effect of exercise interventions. This may be related to factors such as age, health status, or exercise type among female participants. Carter et al. (6) reported that women generally exhibit lower sympathetic responses to stress, which may result in smaller improvements in HRV following exercise interventions. This finding is consistent with Koenig et al. (60), who noted that women typically exhibit higher baseline vagal activity, potentially limiting further HRV improvements through exercise.

In the obesity subgroup, a significant reduction in the LF/HF ratio was observed, indicating that exercise interventions positively modulate ANS function in obese individuals. Obesity is often associated with excessive sympathetic activity and suppressed vagal tone, an autonomic imbalance linked to

metabolic inflammation and increased cardiovascular risk (61). Exercise interventions may improve ANS function through multiple mechanisms, such as reducing metabolic inflammation, enhancing vagal tone, and suppressing sympathetic excitability, thereby restoring ANS balance. Koenig et al. (6) further supported this observation, noting that individuals with higher BMI typically exhibit lower baseline HRV, making them more sensitive to exercise-induced improvements in LF/HF. This underscores the potential importance of exercise interventions in obese populations, particularly for improving autonomic function and reducing cardiovascular risk.

However, moderate heterogeneity was observed in the obesity subgroup ( $I^2 = 67\%$ ), suggesting variability among studies. This heterogeneity may reflect differences in health status, exercise types, and intervention adherence among obese participants. For example, obese individuals may have varying comorbidities (e.g., diabetes, hypertension) that could influence the effects of exercise interventions. Thus, while exercise interventions significantly improved the LF/HF ratio in the obesity subgroup, the heterogeneity calls for cautious interpretation of the results.

The effects of exercise interventions on LF/HF did not differ significantly across regions (P = 0.08). Nonetheless,  $I^2 = 51.3\%$  indicates moderate heterogeneity, which may reflect differences in cultural habits, exercise practices, healthcare systems, and participant characteristics (e.g., diet, physical activity levels, comorbidities) across regions.

Additionally, the results suggest that aerobic and resistance training may yield better intervention outcomes. As long as weekly exercise is maintained and the intervention duration is sufficient (≥8 weeks), both exercise types significantly improved the LF/HF ratio (aerobic training: SMD = -0.57, P = 0.02; resistance training: SMD = -0.56, P = 0.003). This indicates that aerobic and resistance training have unique advantages in modulating ANS balance. Aerobic training may optimize ANS function by enhancing cardiorespiratory fitness, improving blood circulation, and promoting vagal activity (62), while resistance training may achieve similar effects by increasing muscle mass, improving metabolic health, and reducing sympathetic excitability (12). Notably, although both exercise types showed significant effects, no significant difference was found between them (P = 0.84). This suggests that as long as exercise interventions meet certain frequency and duration thresholds, both aerobic and resistance training can effectively improve ANS function. This finding provides flexibility for personalized exercise intervention designs, allowing for the selection of exercise types based on participant preferences, health status, and physical capabilities.

The type of control group significantly influenced changes in LF/HF. The meta-analysis results showed that for intervention groups with a "no exercise intervention" control, the LF/HF ratio decreased significantly (SMD = -0.61, P < 0.001), whereas no significant change was observed for intervention groups with a "low-intensity activity" control (SMD = 0.01, P = 0.97). This result suggests that the improvement in LF/HF ratio when comparing exercise intervention groups to control groups may differ depending on the type of control group.Specifically, when the

control group received "no exercise intervention," the intervention group's LF/HF ratio decreased significantly, indicating a clear effect of exercise interventions on ANS balance. This significant difference may reflect the baseline state of the "no exercise intervention" control group, which was unaffected by any external intervention, thereby more clearly highlighting the positive effects of exercise interventions.When the control group engaged in "low-intensity activity," the difference in LF/HF changes between the intervention and control groups was not statistically significant. This may be because low-intensity activity itself exerts positive effects on ANS function, thereby narrowing the gap between the two groups. This finding suggests that low-intensity exercise may, to some extent, produce effects similar to higher-intensity exercise on the LF/HF ratio. Moreover, low-intensity exercise typically has higher adherence and acceptability, making it a feasible ANS modulation strategy, particularly for older adults or individuals with poor health.

### 4.1 Study strengths and limitations

This study exhibits several strengths. First, it utilized a comprehensive and systematic approach, integrating data from multiple studies to thoroughly explore the effects of long-term exercise interventions on HRV, particularly the LF/HF ratio. Such an approach not only provides an assessment of the overall effects but also underscores the clinical significance of exercise interventions in promoting ANS balance and enhancing cardiovascular health. Second, the study analyzed not only the overall effects of exercise interventions but also systematically examined various potential moderating factors, including health status, gender, BMI, geographic location, and intervention characteristics (e.g., exercise type, duration, frequency). This multidimensional analysis offers valuable theoretical insights for designing personalized exercise intervention programs. Additionally, by conducting an in-depth analysis of intervention characteristics, the study clarified the differential effects of various intervention methods (e.g., aerobic exercise, resistance training) and intervention durations on LF/HF, thereby emphasizing the importance of careful intervention design.

However, this study has several limitations, and the findings should be interpreted with caution. First, significant heterogeneity was observed among the included studies (e.g., high  $I^2$  values), which may stem from differences in participant characteristics (e.g., health status) and intervention protocols (e.g., exercise type, intensity, frequency). This heterogeneity limits the generalizability of the results. Therefore, caution is warranted when interpreting the findings, particularly when applying them to different populations or intervention contexts. Second, although multiple methods were employed to reduce bias (e.g., sensitivity analysis, subgroup analysis), potential publication bias cannot be entirely ruled out, especially given the possible underreporting of negative results. Additionally, it is important to acknowledge that HRV, particularly the LF/HF ratio, serves only as an indirect indicator of ANS activity, reflecting correlations rather than causality, and may be influenced by other confounding factors. Finally, in the subgroup analyses, the limited number of studies in certain subgroups may have resulted in insufficient statistical power, thereby reducing the reliability of the findings. Future research should include more high-quality randomized controlled trials (RCTs) and mechanistic studies to validate these findings and further elucidate the specific mechanisms through which exercise interventions influence the ANS. Moreover, it is recommended that future studies standardize intervention protocols and measurement methods during the design and implementation phases to reduce heterogeneity and enhance the comparability of results.

# **5** Conclusion

The present study indicates that long-term exercise interventions significantly reduce the LF/HF ratio, with particularly pronounced effects observed in populations with diseases and in interventions lasting  $\geq 8$  weeks. Aerobic exercise and resistance training demonstrate strong potential for improvement.

However, these findings should be interpreted with caution. On the one hand, there is substantial heterogeneity among the included studies; on the other hand, data on certain intervention characteristics remain limited. Moreover, since the LF/HF ratio is only an indirect indicator of ANS activity, the observed correlations cannot directly establish causality. Therefore, future research should focus on conducting more high-quality studies to confirm these conclusions.

# Data availability statement

The original contributions presented in the study are included in the article, further inquiries can be directed to the corresponding author.

# References

1. Acharya UR, Joseph PK, Kannathal N, Lim CM, Suri JS. Heart rate variability: a review. *Med Biol Eng Comput.* (2006) 44(12):1031–51. doi: 10.1007/s11517-006-0119-0

2. Shaffer F, Ginsberg JP. An overview of heart rate variability metrics and norms. Front Public Health. (2017) 5:258. doi: 10.3389/fpubh.2017.00258

3. Porges SW. The polyvagal perspective. *Biol Psychol.* (2007) 74(2):116-43. doi: 10. 1016/j.biopsycho.2006.06.009

4. Thayer JF, Yamamoto SS, Brosschot JF. The relationship of autonomic imbalance, heart rate variability and cardiovascular disease risk factors. *Int J Cardiol.* (2010) 141(2):122–31. doi: 10.1016/j.ijcard.2009.09.543

5. Lundstrom CJ, Foreman NA, Biltz G. Practices and applications of heart rate variability monitoring in endurance athletes. *Int J Sports Med.* (2023) 44(1):9–19. doi: 10.1055/a-1864-9726

6. Carter JB, Banister EW, Blaber AP. Effect of endurance exercise on autonomic control of heart rate. *Sports Med.* (2003) 33(1):33-46. doi: 10.2165/00007256-200333010-00003

7. Selig S, Carey M, Menzies D, Patterson J, Geerling RH, Williams AD, et al. Moderate-intensity resistance exercise training in patients with chronic heart failure improves strength, endurance, heart rate variability, and forearm blood flow. *J Card Fail.* (2004) 10(1):21–30. doi: 10.1016/S1071-9164(03)00583-9

8. Hottenrott K, Hoos O, Esperer HD. Herzfrequenzvariabilität und sport. Herz Kardiovaskuläre Erkrankungen. (2006) 31(6):544–52.

# Author contributions

WZ: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing. SB: Data curation, Formal analysis, Resources, Supervision, Writing – review & editing. LL: Writing – review & editing.

# Funding

The author(s) declare that financial support was received for the research and/or publication of this article. This study was supported by the National Natural Science Foundation of China (Project No. 72364006) and the Guizhou Provincial Basic Research Program (Natural Science) Project (Qiankehe Fund for Basic Research-ZK [2023] General 251).

# **Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

# Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

9. Jurca R, Church TS, Morss GM, Jordan AN, Earnest CP. Eight weeks of moderate-intensity exercise training increases heart rate variability in sedentary postmenopausal women. *Am Heart J.* (2004) 147(5):e8. doi: 10.1016/j.ahj. 2003.10.024

10. Hautala AJ, Kiviniemi AM, Tulppo MP. Individual responses to aerobic exercise: the role of the autonomic nervous system. *Neurosci Biobehav Rev.* (2009) 33(2):107–15. doi: 10.1016/j.neubiorev.2008.04.009

11. Kingsley JD, Figueroa A. Acute and training effects of resistance exercise on heart rate variability. *Clin Physiol Funct Imaging.* (2016) 36(3):179–87. doi: 10.1111/ cpf.12223

12. Sandercock GRH, Bromley PD, Brodie DA. Effects of exercise on heart rate variability: inferences from meta-analysis. *Med Sci Sports Exerc.* (2005) 37(3):433–9. doi: 10.1249/01.MSS.0000155388.39002.9D

13. Aubert AE, Seps B, Beckers F. Heart rate variability in athletes. *Sports Med.* (2003) 33(12):889–919. doi: 10.2165/00007256-200333120-00003

14. Kleiger RE, Stein PK, Bigger JT. Heart rate variability: measurement and clinical utility. *Ann Noninvasive Electrocardiol.* (2005) 10(1):88–101. doi: 10.1111/j.1542-474X.2005.10101.x

15. dos Santos Disessa H, Monteiro PHM, da Silva Zacharias V, da Costa Rosa CS, Monteiro HL. A systematic review and meta-analysis investigating the impact of exercise interventions on heart rate variability in hemodialysis patients. *Sci Rep.* (2024) 14(1):30818. doi: 10.1038/s41598-024-81217-0

16. Yang F, Ma Y, Liang S, Shi Y, Wang C. Effect of exercise modality on heart rate variability in adults: a systematic review and network meta-analysis. *Rev Cardiovasc Med.* (2024) 25(1):9. doi: 10.31083/j.rcm2501009

17. Amekran Y, El hangouche AJ. Effect of exercise training on heart rate variability in healthy adults: a systematic review and meta-analysis of randomized controlled trials. *Cureus*. (2024) 16(6):e62465. doi: 10.7759/cureus.62465

18. Gerage A, Forjaz CL, Nascimento M, Januário RSB, Polito MD, Cyrino ES. Cardiovascular adaptations to resistance training in elderly postmenopausal women. *Int J Sports Med.* (2013) 34(9):806–13. doi: 10.1055/s-0032-1331185

19. Jakovljevic DG, Hallsworth K, Zalewski P, Thoma C, Klawe JJ, Day CP, et al. Resistance exercise improves autonomic regulation at rest and haemodynamic response to exercise in non-alcoholic fatty liver disease. *Clin Sci.* (2013) 125(3):143–9. doi: 10.1042/CS20120684

20. Karavirta L, Costa MD, Goldberger AL, Tulppo MP, Laaksonen DE, Nyman K, et al. Heart rate dynamics after combined strength and endurance training in middleaged women: heterogeneity of responses. *PLoS One.* (2013) 8(8):e72664. doi: 10.1371/ journal.pone.0072664

21. Li R, Yan R, Cheng W, Ren H. Effect of resistance training on heart rate variability of anxious female college students. *Front Public Health.* (2022) 10:1050469. doi: 10.3389/fpubh.2022.1050469

22. Ghardashi-Afousi A, Holisaz MT, Shirvani H, Pishgoo B. The effects of lowvolume high-intensity interval versus moderate-intensity continuous training on heart rate variability, and hemodynamic and echocardiography indices in men after coronary artery bypass grafting: a randomized clinical trial study. *ARYA Atheroscler.* (2018) 14(6):260–71. doi: 10.22122/arya.v14i6.1781

23. van Biljon A, McKune AJ, DuBose KD, Kolanisi U, Semple SJ. Short-term highintensity interval training is superior to moderate-intensity continuous training in improving cardiac autonomic function in children. *Cardiology*. (2018) 141(1):1–8. doi: 10.1159/000492457

24. Vernillo G, Agnello L, Barbuti A, Di Meco S, Lombardi G, Merati G, et al. Postexercise autonomic function after repeated-sprints training. *Eur J Appl Physiol.* (2015) 115(11):2445–55. doi: 10.1007/s00421-015-3226-5

25. Toohey K, Pumpa K, McKune A, Cooke J, Welvaert M, Northey J, et al. The impact of high-intensity interval training exercise on breast cancer survivors: a pilot study to explore fitness, cardiac regulation, and biomarkers of the stress systems. *BMC Cancer.* (2020) 20(1):787. doi: 10.1186/s12885-020-07295-1

26. García-Suárez PC, Canton-Martínez E, Rentería I, Moura Antunes B, Machado-Parra JP, Aburto-Corona JA, et al. Remote, whole-body interval training improves muscular endurance and cardiac autonomic control in young adults. *Int J Environ Res Public Health*. (2022) 19(21):13897. doi: 10.3390/ijerph192113897

27. Songsorn P, Somnarin K, Jaitan S, Kupradit A. The effect of whole-body highintensity interval training on heart rate variability in insufficiently active adults. *J Exerc Sci Fit.* (2022) 20(1):48–53. doi: 10.1016/j.jesf.2021.10.003

28. Cassidy S, Vaidya V, Houghton D, Zalewski P, Seferovic JP, Hallsworth K, et al. Unsupervised high-intensity interval training improves glycaemic control but not cardiovascular autonomic function in type 2 diabetes patients: a randomised controlled trial. *Diabetes Vasc Dis Res.* (2019) 16(1):69–76. doi: 10.1177/1479164118816223

29. Benítez-Flores S, Medeiros AR, Voltarelli FA, Iglesias-Soler E, Doma K, Simões HG, et al. Combined effects of very short "all out" efforts during sprint and resistance training on physical and physiological adaptations after 2 weeks of training. *Eur J Appl Physiol.* (2019) 119(6):1337–51. doi: 10.1007/s00421-019-04125-6

30. Philbois SV, Ribeiro VB, Tank J, Reis RMd, Gerlach DA, Souza HCD. Cardiovascular autonomic modulation differences between moderate-intensity continuous and high-intensity interval aerobic training in women with PCOS: a randomized trial. *Front Endocrinol (Lausanne)*. (2022) 13:1024844. doi: 10.3389/fendo.2022.1024844

31. Boutcher SH, Park Y, Dunn SL, Boutcher YN. The relationship between cardiac autonomic function and maximal oxygen uptake response to high-intensity intermittent-exercise training. *J Sports Sci.* (2013) 31(9):1024–9. doi: 10.1080/02640414.2012.762984

32. Zhou W, Wan YH, Chen Q, Qiu Y-R, Luo X-M. Effects of tai chi exercise on cancer-related fatigue in patients with nasopharyngeal carcinoma undergoing chemoradiotherapy: a randomized controlled trial. *J Pain Symptom Manage*. (2018) 55(3):737–44. doi: 10.1016/j.jpainsymman.2017.10.021

33. Cheema BS, Marshall PW, Chang D, Colagiuri B, Machliss B. Effect of an office worksite-based yoga program on heart rate variability: a randomized controlled trial. *BMC Public Health.* (2011) 11(1):578. doi: 10.1186/1471-2458-11-578

34. Chu IH, Lin YJ, Wu WL, Chang YK, Lin IM. Effects of yoga on heart rate variability and mood in women: a randomized controlled trial. J Altern Complement Med. (2015) 21(12):789–95. doi: 10.1089/acm.2015.0138

35. Jones SMW, Guthrie KA, Reed SD, Landis CA, Sternfeld B, LaCroix AZ, et al. A yoga and exercise randomized controlled trial for vasomotor symptoms: effects on heart rate variability. *Complement Ther Med.* (2016) 26:66–71. doi: 10.1016/j.ctim. 2016.03.001

36. Chu IH, Wu WL, Lin IM, Chang YK, Lin YJ, Yang PC. Effects of yoga on heart rate variability and depressive symptoms in women: a randomized controlled trial. *J Altern Complement Med.* (2017) 23(4):310–6. doi: 10.1089/acm.2016.0135

37. Ishaque S, Khan N, Krishnan S. Trends in heart-rate variability signal analysis. *Front Digit Health.* (2021) 3:639444. doi: 10.3389/fdgth.2021.639444

38. Lu WA, Kuo CD. Effect of 3-month tai chi chuan on heart rate variability, blood lipid and cytokine profiles in middle-aged and elderly individuals. *Int J Gerontol.* (2012) 6(4):267–72. doi: 10.1016/j.ijge.2012.01.025

39. Ketelhut S, Ketelhut SR, Ketelhut RG. Effects of school-based highintensity interval training on hemodynamic parameters and heart rate variability: a randomized controlled trial. *J Strength Cond Res.* (2024) 38(6):1033–40. doi: 10. 1519/JSC.000000000004744

40. Collins BEG, Donges C, Robergs R, Cooper J, Sweeney K, Kingsley M. Moderate continuous- and high-intensity interval training elicit comparable cardiovascular effect among middle-aged men regardless of recovery mode. *Eur J Sport Sci.* (2023) 23(8):1612–21. doi: 10.1080/17461391.2023.2171908

41. Alarcón-Gómez J, Calatayud J, Chulvi-Medrano I, Martín-Rivera F. Effects of a HIIT protocol on cardiovascular risk factors in a type 1 diabetes mellitus population. *Int J Environ Res Public Health.* (2021) 18(3):1262. doi: 10.3390/ijerph18031262

42. Kanegusuku H, Silva-Batista C, Peçanha T, Nieuwboer A, Silva ND Jr, Costa LA, et al. Effects of progressive resistance training on cardiovascular autonomic regulation in patients with Parkinson disease: a randomized controlled trial. *Arch Phys Med Rehabil.* (2017) 98(11):2134–41. doi: 10.1016/j.apmr.2017.06.009

43. Zheng S, Kim C, Lal S, Meier P, Sibbritt D, Zaslawski C. The effects of twelve weeks of tai chi practice on anxiety in stressed but healthy people compared to exercise and wait-list groups: a randomized controlled trial. *J Clin Psychol.* (2018) 74(1):83–92. doi: 10.1002/jclp.22482

44. Inbaraj G, Udupa K, Raghavendra RM, Ram A, Patil S, Rajeswaran J, et al. Effects of an 18-week integrated yoga program on cardiac autonomic function in breast cancer patients undergoing adjuvant chemotherapy: a randomized controlled trial. *Integr Cancer Ther.* (2023) 22:15347354231168795. doi: 10.1177/15347354231168795

45. Satyapriya M, Nagendra HR, Nagarathna R, Padmalatha V. Effect of integrated yoga on stress and heart rate variability in pregnant women. *Int J Gynaecol Obstet.* (2009) 104(3):218–22. doi: 10.1016/j.ijgo.2008.11.013

46. Telles S, Sharma SK, Gupta RK, Bhardwaj AK, Balkrishna A. Heart rate variability in chronic low back pain patients randomized to yoga or standard care. *BMC Complement Altern Med.* (2016) 16(1):279. doi: 10.1186/s12906-016-1271-1

47. Bhati P, Hussain ME, Deepak KK, Masood S, Anand P. Progressive resistance training ameliorates deteriorating cardiac autonomic dysfunction, subclinical inflammation, and endothelial dysfunction in type 2 diabetes mellitus: a randomized control trial. *Diabetes Metab Syndr Clin Res Rev.* (2023) 17(5):102778. doi: 10.1016/j.dsx.2023.102778

48. Gallo-Silva B. Effects of water-based aerobic interval training in patients with COPD: a randomized controlled trial. *J Cardiopulm Rehabil Prev.* (2019) 39(2):105–11. doi: 10.1097/HCR.00000000000352

49. Selig S, Carey M, Menzies D, Patterson J, Geerling R, Williams A, et al. Moderate-intensity resistance exercise training in patients with chronic heart failure improves strength, endurance, heart rate variability, and forearm blood flow. *J Card Fail.* (2004) 10(1):21–30. doi: 10.1016/S1071-9164(03)00583-9

50. Songsorn P, Somnarin K, Jaitan S, Kupradit A. The effect of whole-body highintensity interval training on heart rate variability in insufficiently active adults. *J Exerc Sci Fit.* (2022) 19(1):48–53. doi: 10.1016/j.jesf.2021.10.003

51. Krishna BH, Pal P, Pal GK, Balachander J, Jayasettiaseelon E, Sreekanth Y, et al. Effect of yoga therapy on heart rate, blood pressure and cardiac autonomic function in heart failure. *J Clin Diagn Res.* (2014) 8(1):14–6. doi: 10.7860/JCDR/2014/7844.3983

52. Flatt AA, Globensky L, Bass E, Sapp BL, Riemann BL. Heart rate variability, neuromuscular and perceptual recovery following resistance training. *Sports (Basel)*. (2019) 7(10):225. doi: 10.3390/sports7100225

53. Chu I. H., Wu W. L., Lin I. M., Chang Y. K., Lin Y. J., Yang P. C. (2017). Effects of yoga on heart rate variability and depressive symptoms in women: a randomized controlled trial. *J Altern Complement Med*, 23(4), 310–6.

54. Silva LRB, Gentil P, Seguro CS, de Oliveira JCM, Silva MS, Marques VA, et al. High-intensity interval training improves cardiac autonomic function in patients with type 2 diabetes: a randomized controlled trial. *Biology (Basel)*. (2022) 11(1):66. doi: 10. 3390/biology11010066

55. Melanson EL, Freedson PS. The effect of endurance training on resting heart rate variability in sedentary adult males. *Eur J Appl Physiol.* (2001) 85(5):442–9. doi: 10. 1007/s004210100479

56. Tsuji H, Larson MG, Venditti FJ, Manders ES, Evans JC, Feldman CL, et al. Impact of reduced heart rate variability on risk for cardiac events: the framingham heart study. *Circulation*. (1996) 94(11):2850–5. doi: 10.1161/01.CIR.94. 11.2850

57. Deng Y, Zeng X, Tang C, Hou X, Zhang Y, Shi L. The effect of exercise training on heart rate variability in patients with hypertension: a systematic review and meta-analysis. *J Sports Sci.* (2024) 42(13):1272–87. doi: 10.1080/02640414.2024.2388984

58. Howorka K, Pumprla J, Haber P, Koller-Strametz J, Mondrzyk J, Schabmann A. Effects of physical training on heart rate variability in diabetic patients with various

degrees of cardiovascular autonomic neuropathy. *Cardiovasc Res.* (1997) 34(1):206–14. doi: 10.1016/S0008-6363(97)00040-0

59. Carnethon MR, Gidding SS, Nehgme R, Sidney S, Jacobs DR Jr, Liu K. Cardiorespiratory fitness in young adulthood and the development of cardiovascular disease risk factors. *JAMA*. (2003) 290(23):3092–100. doi: 10.1001/jama.290.23.3092

60. Koenig J, Thayer JF. Sex differences in healthy human heart rate variability: a meta-analysis. *Neurosci Biobehav Rev.* (2016) 64:288–310. doi: 10.1016/j.neubiorev. 2016.03.007

61. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association scientific statement on obesity and heart disease from the obesity committee of the council on nutrition, physical activity, and metabolism. *Circulation*. (2006) 113(6):898–918.

62. Picard M, Tauveron I, Magdasy S, Benichou T, Bagheri R, Ugbolue UC, et al. Effect of exercise training on heart rate variability in type 2 diabetes mellitus patients: a systematic review and meta-analysis. *PLoS One.* (2021) 16(5):e0251863. doi: 10.1371/journal.pone.0251863